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Abstract
Current treatments of Parkinson’s Disease (PD), a neurodegenerative disease affecting voluntary 
movement, do not target the underlying pathology, focussing on the symptoms instead.  The focus 
of this study was the usage of a protein involved in the earliest known pathology of PD, α­synuclein 
(α­syn), to conduct preliminary experiments that could determine potential treatments that affect 
aggregation of α­syn.  First, aggregation of α­syn was measured using a commonly used assay for 
detecting protein aggregation, thioflavin T (ThT) fluorescence assay.  Second, Caenorhabditis elegans 
(C. elegans), nematodes more recently used as a low­cost model for diseases, were treated with α­
syn (transgenic species were used overexpressing α­syn in muscle cells and C. elegans were also 
exogenously exposed to α­syn) and observed for any behavioural changes in movement and bend 
speed.  Treating α­syn with hops, an ingredient used in brewing beer, showed a 53­fold reduction in 
fluorescence in the ThT assays performed.  The mechanism in which hops was affecting ThT 
fluorescence was unclear but the effect, regardless, demonstrates its potential use as a treatment 
and warrants further study on its effects on α­syn aggregation. C. elegans overexpressing α­syn and 
exogenously exposed to α­syn showed changes in movement speed compared to untreated 
populations and this study found that exposure to hops reversed the changes in speed possibly 
caused by α­syn.
Abbreviations
PD, Parkinson's disease; ThT, thioflavin T; α­syn, α­synuclein; C. elegans, Caenorhabditis elegans; 
DDP1 (uonEx1 [unc­54::alpha­synuclein::CFP + unc­54::alpha­synuclein::YFP(Venus)]; DDP2 (uonEx2 
[unc­54::CFP::YFP(Venus)];
41 Introduction
1.1 Parkinson’s Disease
Parkinson’s Disease (PD) is a neurodegenerative disease with cases developing in 1 in 50 people over 
the age of 65 (Schapira, 2009). The average duration of PD from diagnosis to death is 15 years with
an increasing severity of motor and non­motor symptoms developing over the course of the disease
(Lees et al., 2009). The severity of PD and its increasing occurrence call for more effective 
treatments than the standards used.
PD is typically diagnosed when a patient demonstrates four cardinal motor symptoms 1) 
bradykinesia (slow movement), 2) rigid joint movement, 3) resting tremors, and 4) postural 
instability (Postuma et al., 2015). Resting tremors are classified as a 3­ to 6­Hz distal resting tremor 
(Gelb et al., 2008). PD is usually diagnosed by the four symptoms listed, but also includes gait 
freezing (freezing while walking) or festination (a random increase in walking speed), blink rate and 
speech abnormalities (Lees et al., 2009). PD also includes several nonmotor symptoms described 
next.
Nonmotor symptoms include autonomic dysfunction and cognitive dysfunction (Zesiewicz et 
al., 2006). The most common autonomic symptom in PD is orthostatic hypotension, a drop in blood 
pressure within 3 minutes of standing; PD patients can also develop abnormal thermoregulation, 
gastrointestinal or urinary tract dysfunction, or impotence (Gelb et al., 2008). Examples of cognitive 
dysfunction in PD are dementia, depression and hallucinations.  These symptoms are less prevalent 
in all PD patients, but still impair quality of life and occur in 25­40% of PD cases (Gelb et al., 2008).
The motor and non­motor symptoms become more severe as PD progresses and treatments 
currently do not target the pathophysiology allowing disease symptoms to worsen over time. The 
pathophysiology is outlined next with a brief history in PD research to provide insight into more 
effective treatments that can halt progression.
51.2 Venus Principle pathology in PD
The earliest recorded characterisation of PD was a description of symptoms by James Parkinson in 
1817 (Parkinson, 1817).  Nearly a century later in 1912, Fritz Jakob Heinrich Lewy described 
inclusions in cell bodies found in several brain regions of subjects with PD (Brundin and Melki, 2017).
Over 200 years after the first description of PD symptoms, the initial cause of PD is still unknown, 
however, research points to two major pathophysiological characteristics in PD, degeneration of the 
nigrostriatal pathway and cytoplasmic inclusions.
The first major pathology discussed is the degeneration of the nigrostriatal pathway in the 
basal ganglia.  Nerve cell loss was found in post mortem PD patients in the ventrolateral nerve cell 
group of the substantia nigra, and less neuronal loss in the dorsomedial group (Goedert et al., 2017).  
The regions containing the most lesions were part of the dopaminergic network of neurons in the 
nigro­striatal pathway (dopamine neurotransmitter acting at the synapse) (Beyer et al., 2009).  PD 
pathology was linked to the dopaminergic projections mentioned and the first clue to a possible 
cause was the cytoplasmic inclusions found at the sites of neuron death.
1.2.1 Lewy Bodies
The cytoplasmic inclusions would come to be known as Lewy bodies, the other defining 
characteristic of PD pathology (Pollanen et al., 1993).  Several years after the first description of 
Lewy bodies by Heinrich, in 1919, researcher Tretiakoff described the presence of Lewy bodies in the
pars compacta of the substantia nigra (see Figure 1.1 A) (Tretiakoff, 1919). Later, researchers also
found inclusions in the dorsal motor nucleus of the vagus nerve, the nucleus basalis of Meynert and 
some thalamic nuclei of PD patients (Goedert et al., 2017). The Lewy bodies were localised to these 
regions as opposed to being widespread in all brain regions. The brain regions containing Lewy 
bodies are identified and the physical characteristics of Lewy bodies are described next.
6Figure 1.1 (A) Sagittal cross­section illustration of human brain, (B) coronal cross­section illustration of human brain 
highlighting the position of the pars compacta region of the substantia nigra shown in panel A.  Pg. 118, 345; Siegel, A., & 
Sapru, H. N. (2011). Essential neuroscience (2nd;2; ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health.
Lewy bodies are 8–30 µm wide spherical structures that are eosinophilic (eosin stain left of the black 
arrow with a darker pink stain in panel A of Figure 1.2) (Olanow et al., 2004). Lewy bodies in
neurons of the substantia nigra observed with an electron micrograph in panel B Figure 1.2 have a 
darker stained central core (dense granular material indicated by the white arrow) and a ring of 
filaments stained around the core (radiating filaments of 7–20 nm in diameter; black arrow in Figure 
1.2 B) (Olanow et al., 2004; Beyer et al., 2009).
Figure 1.2 Images of Lewy bodies (A) in dopamine neurons of the substantia nigra with eosin stain, (B) electron micrograph 
showing the dense core and filaments.  Page 497 (Olanow et al., 2004)
The second important PD pathology involves one of the key components of Lewy bodies.  Lewy 
bodies were found to be made of more than 76 components, which belong to 10 different protein 
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7classes such as structural elements, proteins involved in cellular responses, phosphorylation, signal 
transduction, cell cycle, cytoskeletal and cytosolic proteins (Beyer et al., 2009). The main 
component of Lewy bodies was the protein α­synuclein and the previously mentioned components 
were thought to be captured after the initial structure comprising α­synuclein is formed (Beyer et al., 
2009).  Although, Lewy bodies are a pathological marker of PD, researchers found that Lewy bodies 
are not cytotoxic because there was no correlation between neuronal loss and the formation of 
Lewy bodies (Hill and Tompkins, 1997; Tanaka et al., 2004) and instead, may be cytoprotective 
aggresomes, inclusions that degrade excessive amounts of, or dysfunctional proteins (Taylor et al., 
2003; Olanow et al., 2004; Tanaka et al., 2004). Lewy bodies also share similar development 
processes with aggresomes, making them less likely to be responsible for the spreading 
degeneration in PD (McNaught et al., 2002). Alpha­synuclein being the main component of Lewy 
bodies became a new research priority because of its possible link to the origin of PD pathology.
1.3 Alpha­synuclein
Alpha­synuclein (α­syn) is a protein found near presynaptic terminals, encoded by the SNCA gene,
with the highest levels found in the neocortex, hippocampus, substantia nigra, thalamus and 
cerebellum (Kim et al., 2014). Human α­syn contains 140 amino acids with a molecular mass of 
approximately 14 kDa (Ghosh et al., 2017).  While the function of α­syn is unknown there is some 
evidence to indicate that α ­syn may regulate neurotransmitter synthesis, release and vesicular 
storage (Cheng et al., 2011).  In PD, Lewy bodies comprising of α­syn are an identifying factor of the 
disease. Alpha­syn could play an important role either initiation or progression of PD, hence, what 
researchers currently know about where α­syn is found and its functions are explored next.
In 1988, Maroteaux et al., (2018) identified α­syn in neuronal cell soma and found that it 
mostly localised at the synaptic nerve terminal. The localisation of α­syn was determined using light 
and electron microscopy; cross sections were stained with synuclein fusion protein antibody and 
fluorescein­conjugated wheat germ lectin, fluorescence was greatest near the nerve terminals.
Later research involving immunostaining of rat brain tissue revealed α­syn was in abundant in the 
8neocortex, hippocampus, olfactory bulb, striatum, thalamus, and cerebellum and less abundant in 
the brain stem (Iwai et al., 1995). These are also the areas that contain Lewy bodies or 
neurodegeneration.
After identifying where α­syn localises in the body, researchers investigated the possible 
function of α­syn. Researchers showed α­syn may inhibit dopamine synthesis by influencing enzyme 
activity of tyrosine hydroxylase (TH) (Cheng et al., 2011).  TH is an enzyme that catalyses the 
hydroxylation of tyrosine to L­dopa, which is converted to dopamine by an aromatic amino acid 
decarboxylase, making TH a rate­limiting enzyme in dopamine synthesis (Daubner et al., 2011).  
Alpha­syn is thought to most likely reduce the phosphorylation of TH, bind with TH in a 
dephosphorylated state, and maintain TH in an inactive form, all of which result in reduced 
dopamine synthesis (Cheng et al., 2011).
Alpha­syn may also affect vesicular storage and release of dopamine.  Entry of dopamine 
into vesicles is controlled by vesicular monoamine transporter 2 (VMAT2) (Daubner et al., 2011).  
Overexpression of α­syn caused down­regulation of VMAT2 and increased dopamine release into 
cytosol, whereas knockdown of α­syn increased dopamine vesicular storage (Cheng et al., 2011).  
Any effect on α­syn was shown to directly affect dopamine activity demonstrating the protein’s role 
in regulating neurotransmitter synthesis and release.
Although the exact mechanisms of α­syn function are yet to be determined, this protein 
plays a positive role in neurotransmitter activity and some factor or incident causes the protein to 
aggregate in PD.  Alpha­syn is an intrinsically disordered protein that can bend into different shapes 
and is susceptible to aggregation because of its flexible structure, unlike ordered proteins that exist
in stable 3­dimensional structures (Frimpong et al., 2010; Breydo et al., 2012). As an amyloid 
protein, α­syn is prone to aggregation, however very little aggregation is observed in normal 
individuals.  Since greater than 90% of PD cases are idiopathic in nature with no known genetic cause 
(Rocca et al., 2004; Deleidi and Gasser, 2013; Ghosh et al., 2017).  The challenge faced then is to 
9identify what causes idiopathic PD.  If not a genetic mutation, what pathology is first induced which 
then spreads throughout the brain leading to the syndrome referred to as PD.  Aggregation of α­syn 
appears to be one of the earliest pathologies associated with the disease, and so it is likely that any 
potential initiating trigger may be associated with disruption to or aggregation of this protein (Braak 
et al., 2003; Danzer et al., 2007).  In the next section we will examine evidence presented in the 
literature that suggest α­syn is involved in the earliest stages of the disease and therefore how 
disruption of α­syn aggregation may therefore represent a promising avenue of investigation as a 
potential mechanism for treating the disease.
1.3.1 Alpha­syn pathology
The aggregation pathway of α­syn is still unclear but outlined next are some possible aggregation 
pathways based on recent research (Ghosh et al., 2017). The original consensus was that α­syn
proteins existed in the cytoplasm as single molecules referred to as monomers in this study.  After 
being examined in non­denaturing conditions, researchers discovered that endogenous α­syn exist 
as stable folded tetramers that do not easily aggregate (~58kDa) (Ahmad and Lapidus, 2012; Kim et 
al., 2014). According to this evidence, an extra step in the aggregation process might occur, 
destabilising the tetramers and allowing monomeric α­syn to aggregate. The initial molecular 
structures thought to be formed were dimers, two α­syn molecules bound together (~29 kDa) (Kim 
et al., 2014).
After dimer formation, different α­syn oligomer species were shown to form in vitro
(Cremades et al., 2017).  The mechanism in which the different oligomer species form is unknown, 
however, the physical characteristics of these species were described in vitro (Danzer et al., 2007).
Two unique archetypes of oligomers were observed, spherical and ring shaped (Ghosh et al., 2017).  
The two species of oligomer are an intermediate between monomeric α­syn and the fibrillar Lewy 
Bodies; they are functionally different to each other.
Of the two species, the spherical oligomers showed no cytotoxic effect (Danzer et al., 2007), 
but nonetheless, showed a characteristic that could be important in PD.  SH­SY5Y human 
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dopaminergic neuroblastoma cells exposed to spherical oligomers caused intracellular aggregation 
of α­syn (Danzer et al., 2009).  The seeding effect of these oligomers falls in line with the 
understanding that PD is progressive.  Further studies showed the possible means in which 
oligomers spread from neuron to neuron (Luk et al., 2009, 2012).
Originally, researchers thought oligomers spread to other neurons by membrane leakage 
from dying cells, but this was overlooked because α­syn released from dying cells did not propagate 
to other neurons (Ottolini et al., 2017). In vitro, extracellular oligomers were up taken by human H4 
neuroglioma cells via exosomes (small vesicles with sizes between 60–100 nm) (Danzer et al., 2012).
The oligomers were both inside the vesicular space of exosomes and bound to the outside surface of 
exosomes.  Exosome bound oligomers were more likely to be taken up by neighbouring neurons 
than unbound oligomers and were also more likely to be cytotoxic (Danzer et al., 2012). Exosomal 
uptake of oligomers explains the first part of α­syn propagation linked to the spreading 
neurodegeneration found in PD.
The second part of propagation involves axonal transport.  Once inside the neuron, 
oligomers still need to travel along the axon to reach other neurons.  The method in which axonal 
transport occurs is under debate because the anterograde axonal pathway becomes degraded over 
time (Li et al., 2010; Tang et al., 2012; Ottolini et al., 2017). The oligomers are thought to hinder
microtubules and kinesin motors responsible for anterograde transport (from cell body to synapse) 
without affecting dynein mediated retrograde transport (synapse to cell body) (Ottolini et al., 2017).  
Oligomers are thought to travel along the axon from synapse to the cell body, after fibrillar a­syn
was monitored using live­cell imaging and immunofluorescence to characterize the transport of 
fluorescent a­synuclein fibrils and their transfer to second­order neurons (Freundt et al., 2012).  
Although more research is required to ascertain the exact mechanism of α­syn propagation, growing 
evidence indicates exosomal uptake and retrograde transport are the probable means of 
propagation.
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Continued research showed the transmission of α­syn from the stomach to the brain along 
the vagus nerve using female Sprague­Dawley rats (Ulusoy et al., 2017), further supporting the 
uptake and transfer of α­syn.  Although these results did not specify exosomal uptake or axonal
transport, these findings also demonstrate that α­syn is being transmitted from to neuron to neuron, 
highlighting the need to stop the spread of α­syn oligomers.
The final mechanism of PD pathology involving oligomers to be discussed is neuronal death, 
mostly but not limited to dopaminergic neurons (Paleologou et al., 2009; Agosta et al., 2013; 
Daviaud et al., 2014). Originally, the Lewy body deposits found in post mortem PD brains were 
thought to be cytotoxic, however, researchers later discovered that ring­shaped α­syn oligomers
were actually the species causing apoptosis (Chen et al., 2015).  In vitro, ring­shaped α­syn oligomers
bound to the cell membrane disrupting the lipid bilayer (Cremades et al., 2017), forming pore­like 
channels (Breydo et al., 2012). Oligomers caused cytotoxicity in cell cultures by triggering an influx 
of calcium into cells through the newly formed channels, affecting mitochondrial function (Danzer et 
al., 2007), causing cell death through caspase­3 activation (Dehay et al., 2015); caspase­3 is a 
protease that mediates apoptosis in neurons (D’Amelio et al., 2010).
Most research points to α­syn oligomers as the main cause of progression in PD severity and 
continual degeneration of neurons (Hashimoto et al., 1997; Irizarry et al., 1998; Danzer et al., 2007, 
2009; Saito et al., 2016) rather than the Lewy bodies, which are thought to be cytoprotective and 
not cytotoxic (Olanow et al., 2004; Tanaka et al., 2004).  Current PD treatments, however, do not 
target oligomers or any mechanisms linked to their spreading toxicity and allow PD symptoms to 
worsen overtime. One of the aims in this study is to target the aggregation process of α­syn in vitro 
to prevent oligomer formation, which would prevent uptake, seeding and cytotoxicity.
1.4 Treating PD
The primary therapeutic treatments of PD treat symptoms by targeting the deficiency of dopamine 
in the dopaminergic neurons; the treatments most commonly used are levodopa, mono amine 
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oxidase inhibitors (MAO), and dopamine agonists (Lees et al., 2009).  The mechanism of these 
treatments is to increase the reduced dopamine levels in PD. The loss of dopamine is likely due to 
the loss of dopaminergic neurons (Daviaud et al., 2014) thought to be caused by toxic α­syn 
oligomers (Danzer et al., 2007), however, based on the research of α­syn function and its control of 
dopamine release (Yavich et al., 2004), less dopamine could be available at the synapse due to the 
loss of functional α­syn. None of the treatments stop the underlying disease process of 
neurodegeneration, and only help alleviate some of the motor symptoms caused by 
neurodegeneration.  The mechanisms and disadvantages of current treatments will be described to 
demonstrate why there is a need for a new treatment that targets the earliest known origin of PD 
pathology, α­syn aggregates.
1.4.1 Levodopa
The standard and most prescribed treatment for PD is dopamine replacement with levodopa (Lees 
et al., 2015).  Levodopa is used instead of dopamine because it can cross the blood brain barrier 
whereas dopamine cannot.  It is an amino acid that is converted to dopamine by dopaminergic 
neurons after it bypasses the blood brain barrier (Haddad et al., 2018).  Levodopa treats PD by 
replacing lost dopamine at dopaminergic synapses in the brain and is currently the most effective 
treatment in PD (Bereznicki, 2010).
The first issue that was resolved with levodopa treatments was the low bioavailability 
because of decarboxylation by the enzyme amino acid decarboxylase (Freitas et al., 2016).  This was 
resolved by administration of a decarboxylase inhibitor with treatments.  Even after levodopa
bioavailability is increased, continued use causes dyskinesia and involuntary movement from 
response fluctuations (Lees et al., 2009).  After long term use, PD patients require increased doses 
due to diminishing therapeutic action (Freitas et al., 2016). A solution to the dramatic fluctuation in 
dopamine levels and the reduced effectiveness occurring with levodopa usage was to administer 
dopamine agonists with longer half­lives such as ropinirole as a first line treatment (Lees et al., 2009; 
Rascol et al., 2015).  Using dopamine agonists, would provide a more continuous administration of 
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dopamine to dopaminergic neurons, reduce dopamine fluctuation and delay the required use of 
levodopa (Schapira, 2009).
1.4.2 Dopamine agonists
Dopamine agonists such as ropinirole are also effective in treating PD and their longer half­life 
provides continuous dopaminergic stimulation compared to levodopa (Schapira, 2009). Dopamine 
agonists do not cause dyskinesia, but they are not as effective as levodopa (Kulisevsky and 
Pagonabarraga, 2010), making them useful in delaying the use of levodopa.
1.4.3 MAO inhibitors
Another treatment used in PD is MAO inhibitors, which work by inhibiting enzymes that break down 
dopamine thereby increasing dopamine availability at the synapse (Schapira, 2009). MAO inhibitors 
are not as potent as levodopa when treating the motor symptoms because when the dopaminergic 
neurons die, the rate of metabolism becomes greater than the rate of dopamine preserved by MAO 
inhibitors (Lees et al., 2009).  However, using MAO inhibitors in the early stages of PD may delay 
disease progression (Lees et al., 2009).  The combined therapy of levodopa and MAO inhibitors both 
reintroduce lost dopamine and prolong its availability (Schapira, 2009).
Although more effective methods of replacing dopamine are now used, they still do not treat 
postural instability and cognitive symptoms like dementia.  The symptoms that develop in the later 
stages of PD as a result of disease progression put patients at risk of injury making the need for a 
treatment that targets the original pathology of PD (Schapira, 2009).
To find better treatments for PD, researchers used different models to further elucidate the 
underlying pathology of PD and investigate possible therapies.  This study aims to add a preliminary 
model that requires less time to undertake, allowing careful refinement of therapies before using 
larger animal models.  The commonality between all the current treatments used to treat PD is that 
they do not treat the earliest known pathology of PD.  They do not treat the cytotoxicity caused by 
α­syn oligomers.  Hence, the first aim of this study was to optimise a protocol for an assay that 
examines the rate of α­syn aggregation that can be used to test treatments that target α­syn 
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aggregation and prevent oligomer formation. The following section discusses how treatments 
should be chosen for testing using the assay and what was the first treatment tested in this study.
1.5 Approaches to discovering PD treatments
This section will go through the general drug discovery process and the current process used in PD.  
There are several approaches and pathways to discovering new treatments for diseases. The first 
phase is usually identifying the treatment of the target (Hughes et al., 2011).  Target identification is 
followed by assay development that examines the effects of the treatment on the target. The next
phase is the screening process for different compounds that will be used in the assays.  The final
phases involve hit identification and lead optimisation of compounds, in which compounds are 
selected based on characteristics based on potency and bioavailability (Waring, 2010). The final
phases are not discussed in detail because they are not the focus of this study.
1.5.1 PD treatment target
The first phase in finding a potential treatment is identifying the treatment of the target (Hughes et 
al., 2011).  The target can be proteins, genes or RNA involved with the disease or its progression. In 
PD, the earliest known pathology is the development of oligomeric α­syn species as mentioned 
earlier, making α­syn aggregates a target for treatments.  The origin of PD is unknown and cannot be 
targeted, however, a treatment that targets the earliest pathology that is known to cause neuronal 
degeneration can delay or prevent the progression of PD. Targets other than the α­syn pathology
will be described to illustrate some of their benefits and why targeting the earliest pathology is the 
most promising.
1.5.1.1 Dopamine depletion
Reducing dopamine levels was one of the early models of PD because of the onset of PD like 
symptoms reproduced by this model.  Altering dopamine levels was one of the first models that led 
to the discovery of the gold standard of PD treatment, levodopa (Lees et al., 2015).  The 
administration of reserpine depleted dopamine levels and caused PD like symptoms by inhibiting the 
vesicular transporter of monoamines (VMAT2) (Leão et al., 2015).  Levodopa was used to reverse the 
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reduced levels of dopamine caused by reserpine administration, thereby, reversing the symptoms 
induced (Lees et al., 2015).  As impactful as the reserpine model of PD was, reserpine did not mimic 
the pathology found in PD.  Most current research is focused on neurotoxic and transgenic models of 
PD because those models better emulate the neuronal loss seen in PD (Leão et al., 2015).  Since 
reserpine works by reducing dopamine levels, this model does not allow researchers to understand 
the documented loss of neurons.
1.5.1.2 Dopaminergic neurotoxins
The models discussed next are those that mimic the neurodegeneration found in the nigrostriatal 
dopaminergic pathways.  6­hydroxydopamine (6­OHDA) is a neurotoxin that causes lesions at the 
site of injection (Stott and Barker, 2014).  6­OHDA selectively targets catecholaminergic transporters, 
but requires correct dosing, injection technique, injection site and other factors to ensure the brain 
region being studied is targeted (Sachs and Jonsson, 1975).  Treating rats with 6­OHDA allowed 
researchers to test possible PD therapies such as curcumin, which showed a neuroprotective effect 
against 6­OHDA exposure (Zbarsky et al., 2005).  The 6­OHDA model does not involve α­syn or result 
in inclusions at the sites of degeneration (Duty and Jenner, 2011; Stott and Barker, 2014).  Instead, 
the 6­OHDA model relies on the remaining presence of tyrosine hydroxylase­stained cells to 
determine a therapy’s effects.  This model can still be used to discover new treatments for PD, but 
not specifically those that target α­syn pathology.
Another neurotoxin used to model neurodegeneration in PD is 1­methyl­4­phenyl­1,2,3,6­
tetrahydropyridine (MPTP) (Müller and Bohnen, 2013).  MPTP is a toxin with an affinity to 
dopaminergic neurons (Muñoz­Manchado et al., 2016).  MPTP PD models helped identify possible 
mechanisms of neuron death in PD and similar to 6­OHDA administration, MPTP was injected 
directly into the brain regions being studied (Noelker et al., 2013).  Using MPTP in this way, however, 
resulted in rapid cell death as opposed to the progressive degeneration found in PD.  Unlike 6­OHDA, 
researchers later showed that consistent low doses of MPTP can better model progressive 
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degeneration of PD (Muñoz­Manchado et al., 2016), but the remaining disadvantage of an MPTP
model is the lack of α­syn pathology.
Rotenone is a more recent neurotoxin used to model PD that inhibits mitochondrial complex 
I (Tanner et al., 2011).  Rotenone causes neuron death at exposure sites like MPTP and 6­OHDA, and 
can also cause most of the movement disorders found in PD along with Lewy body formation (Panov 
et al., 2005; Maturana et al., 2015).  The main limitation of the rotenone model is in the variability of 
subjects that develop nigrostriatal lesions, but new research shows that intraperitoneal 
administration increases reproducibility (Cannon et al., 2009).  Of the three models described, 
rotenone shows the most similarity to PD pathological manifestations and could be the model of 
choice when working with larger subjects such as rodents.
1.5.1.3 Transgenic
The final class of PD models discussed here is the use of transgenic species, consisting of either 
knockout or overexpression of genes associated with PD. Knockout models proved to be pertinent 
to PD because knockout mice with targeted deletion of α­syn showed reduced impulsivity (Peña­
Oliver et al., 2012) and some impairment with dopamine and glutamate release (Gureviciene et al., 
2007), however, these models demonstrate the long term effect of the loss of α­syn function
(Greten­Harrison et al., 2010) rather than the cytotoxicity and the reason why α­syn is losing its 
function (Rieker et al., 2011). Transgenic models can be used to mimic the α­syn pathology involved
in PD depending on the genes that are overexpressed, and the animal species used (Blesa and 
Przedborski, 2014).
Some of the different transgenic animal models used in previous PD research are mice, 
Drosophila, C. elegans and zebrafish (Duty and Jenner, 2011).  Mice overexpressing human α­syn 
demonstrated substantial atrophy and reduced brain volume (Haggerty et al., 2011).  Other studies 
looking at the overexpression of wildtype mouse ortholog (m α­syn) also showed pathological 
changes resembling those found in post­mortem human PD because of the strong α­syn staining in 
the brainstem and cerebellum (Rieker et al., 2011).
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Drosophila expressing human α­syn showed a reduction in climbing ability, which was 
reversed when treated with L­DOPA (Pendleton et al., 2002). Haywood and Staveley (2004) also 
showed a reversal in α­syn­induced premature loss of climbing ability of Drosophila using conditional 
expression of parkin, a gene that encodes for ubiquitin protein ligases.  Ubiquitin protein ligases act 
to identify damaged or misfolded proteins to facilitate the attachment of a number of ubiquitin 
monomers of these proteins and are targeted to the proteasome (Haywood and Staveley, 2004).
Transgenic C. elegans expressing A30P or A53T mutant α­syn failed to control locomotory 
rate in response to food and showed a reduction in neuronal dopamine content (Kuwahara et al., 
2006).  Transgenic Zebrafish, 3­4 cm long vertebrates, were modified with the deletion of leucine­
rich repeat kinase 2 (LRRK2) (Prabhudesai et al., 2016).  LRRK2 mutations are one of the most 
common causes of genetic PD and knocking out LRRK2 in zebrafish, caused a loss of dopaminergic 
neurons and reduced swimming distance (Duty and Jenner, 2011; Prabhudesai et al., 2016).  The 
different transgenic models discussed all demonstrated some form of α­syn pathology and in many 
cases are proving useful in treatment discovery.  The study described in this thesis also attempted to 
add a novel means of administering α­syn to c elegans to try and induce α­syn pathology, without 
the need to generate genetically modified organisms.  The method proposed, to induce α­syn 
pathology by feeding exogenous α­syn is non­invasive, and technically very easy to do using existing 
standard lab equipment.  This model will be discussed below.
1.5.1.4 Alpha­syn aggregation
More research is being done to target the aggregation of α­syn to screen for PD treatments. Several 
studies tested treatments targeting α­syn aggregation because of the toxicity of oligomers and 
because this is the earliest known pathology in PD (Giehm et al., 2011; Daturpalli et al., 2013; Macchi 
et al., 2016).  The studies used different assays and techniques to measure the effects of a treatment 
on aggregation.  Some of these assays and techniques are discussed next.
Exogenous exposure to α­syn was considered a valid means of treatment administration in 
this study because of research showing prion presence in blood via nasal and oral exposure in 
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hamster and deer (Elder et al., 2015).  Research pertaining to PD also showed that α­syn can travel 
through the vagus nerve in rats from the gut to the brain (Holmqvist et al., 2014) and from the brain 
to the gut (Ulusoy et al., 2017).  Both findings are important because the gut­brain transfer 
represents a means of contracting α­syn pathology and possibly PD through feeding.  The brain­gut 
transfer shows that α­syn pathology could be infectious.  Since C. elegans have a much more 
simplified digestive tract consisting of only 100 cells that serve as the pharynx, intestine and rectum 
(Kormish et al., 2010), they should be more susceptible to α­syn pathology through feeding.  The 
simplicity of the digestive tract and the high concentrations of α­syn used in this study increase the 
likelihood of α­syn uptake.  Past studies also showed that transgenic C. elegans exposed to E. coli
producing the extracellular bacterial amyloid protein curli exhibited enhanced α­syn aggregation
(Chen et al., 2016).
1.5.2 PD assay development
Target identification is followed by assay development that examines the effects of a treatment on 
the target. Assays can be in vitro or in vivo with examples of each found in the literature.  In vitro 
assays typically include the use of colorimetric or fluorescence assays to measure a response or an 
affinity to the selected target (Hughes et al., 2011).  One of the most commonly used in vitro assays 
in measuring α­syn aggregation is the thioflavin T assay (Lee and Lee, 2002; Voropai and Samtsov, 
2003; Niidome et al., 2007; Giehm et al., 2011; Ono et al., 2012; Daturpalli et al., 2013; Wördehoff et 
al., 2015). Thioflavin T (ThT) is a yellow dye that was shown to fluoresce in the presence of amyloid 
β­sheets (Wördehoff et al., 2015).  The ThT assay is one among many different techniques used to 
visualise the aggregation of α­syn.
1.5.2.1 In vitro
Other in vitro assays include light scattering, dynamic light scattering (DLS), small angle X­ray 
scattering, transmission electron microscopy (TEM), atomic force microscopy (AFM), far­UV circular 
dichroism, Fourier transform infrared spectroscopy (FTIR) and fibre X­ray diffraction (Giehm et al.,
2011).  Light scattering is one of the least sensitive to detection of aggregates of the techniques
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listed.  Although optimisations of this technique exist for DNA (Feng et al., 2011), other techniques 
require fewer optimisations.  Dynamic light scattering, unlike light scattering, is highly sensitive to 
aggregates, but this is both useful for detecting low concentrations of aggregates and impractical 
because of the necessity to have highly pure samples (Giehm et al., 2011).  X­ray scattering, TEM, 
AFM, far­UV circular dichroism, FTIR and fibre X­ray diffraction allow a greater level of visualisation 
compared to using a fluorescence assay. The limitation for these techniques is the inability to 
conduct high throughput testing of treatments (Giehm et al., 2011).  The use of the ThT assay to 
detect α­syn in vitro is prevalent in research because it balances sensitivity and high throughput 
screening (Lee and Lee, 2002; Voropai and Samtsov, 2003; Niidome et al., 2007; Giehm et al., 2011; 
Ono et al., 2012; Daturpalli et al., 2013; Wördehoff et al., 2015).
1.5.2.2 In vivo and ex vivo assays
In vivo or ex vivo assays can also be used to measure the effects of a treatment. Ex vivo assays 
encompass cell culture, using distinct cell lines and in vivo, animal models using different species.
Cell cultures and animal models each provide a different insight to the effects a treatment has on 
the target. (Anders and Vielhauer, 2007)
Cell cultures provide a model that leaves out the complexity of a full organism and they 
allow researchers to observe the effects of a treatment on individual cells and interactions between 
cells without the need for ethics committee approval.  The ability to monitor interactions between 
cells was used to observe the spread of oligomeric proteins from cell to cell using the SH­SY5Y 
neuron cell line (Freundt et al., 2012; Krauss and Vorberg, 2013).  Studies also observed the 
cytotoxicity of oligomers using SH­SY5Y (Danzer et al., 2007; Schlachetzki et al., 2013). Using cell 
cultures to test treatments and study disease will remain a powerful research tool, but one of the 
main drawbacks considered by this study is the susceptibility to contamination.
Before mentioning the species used in this study other species will be examined to address 
the reasons they were not selected.  There are many species used in vivo models for studying 
diseases.  Some of the mammalian species include: monkeys, pigs, rat, mouse, rabbit (Ribeiro et al., 
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2013; Vaquer et al., 2013).  Miniature pigs are usually used in research because of anatomical, 
physiological, and genetic similarities to humans; they have a fully gyrencephalic brain and as adults 
have an equal ratio of cerebral white and grey matter, comparable to that in humans (Conrad et al., 
2014; Ryan et al., 2018).  From mammals, rodents are the main animal order used for developing 
disease models (Anders and Vielhauer, 2007).  Rodents are used because of their high reproduction 
rate (Lohmiller and Swing, 2006) and their handling ease (Koch, 2006), however there are species 
that have an even greater reproduction rate at a smaller cost.
The use of mammals involves a greater maintenance cost and requires ethics committee 
approval whereas smaller non­mammalian models such as drosophila or C. elegans require no 
approval and little maintenance costs (Lim, 2010).  C. elegans is a species gaining research interest in 
neurodegenerative disease because of documented neuronal loss and behavioural changes with the 
overexpression of α­syn (Raslan and Kee, 2013).  C. elegans allow the study of cell interactions like 
cell cultures and behavioural analysis like other animal models (Harrington et al., 2010; Risley et al., 
2016).  C. elegans do not require any ethics committee approval like other animal models and have 
shorter life spans with a high reproduction rate.  A population with high statistical power can be 
achieved within a few weeks of breeding and multiple studies can be conducted within this same 
time frame (Harrington et al., 2010).
Compared to other invertebrate species like drosophila, another commonly used 
invertebrate in modelling disease (Whitworth et al., 2006), C. elegans is also advantageous because 
of the limited movement on a 2­D plane allowing easier video analysis.  Both drosophila and C. 
elegans allow high throughput screening, but the ease in handling C. elegans made its use more 
feasible for behavioural analysis in this study.
C. elegans as subjects allow a high throughput level of testing treatments because of their 
short life span and high reproduction rate allow greater statistical power than mammal models.  This 
leads to another aim, which was to develop an α­syn pathology in C. elegans that can be used to test 
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the effects of different treatments that can reverse any behavioural changes. This would be done by 
exogenous exposure to α­syn and then measuring movement speed of the nematodes.
1.5.3 Treatment screening
After developing assays to screen treatments, a method of selecting treatments needs to be 
considered.  There are several screening strategies which include: high throughput, focused screen, 
fragment screen, structural aided drug design, virtual screening, physiological and nuclear magnetic 
resonance (Hughes et al., 2011). The most time­consuming method of screening would be high 
throughput screening, which is screening the whole library of compounds (Hughes et al., 2011).  The 
other methods involve a categorization of compounds that are more likely to bind or affect the 
target.
The goal of focused, structure based, and virtual screening is to reduce the number of 
compounds to be tested.  Compounds found in online databases are selected based on their 
structures by either virtual high throughput testing or selection according to specific structures 
(Sliwoski et al., 2014).  To further reduce the number of compounds to test, other studies used 
automated datamining to determine which herbs and constituents from the literature could treat 
neurodegenerative disease (Harvey, 2008; Ke et al., 2016).
The treatment chosen in this study was hops because of its polyphenol content (Liu et al., 
2014).  Polyphenols are thought to be neuroprotective because of the inhibition of amyloid 
formation (Porat et al., 2006; Pandey et al., 2008; Singh et al., 2013; Magalingam et al., 2015).
Polyphenols such as curcumin were shown to inhibit the aggregation of α­syn both in vitro using a 
colorimetric assay and in vivo using catecholaminergic SH­SY5Y cell lines with red fluorescent protein 
(DsRed2) fused with an A53T mutant of α­syn (Pandey et al., 2008).  The polyphenol present in hops 
is the flavonoid xanthohumol, which was shown to reversibly inhibit α-Glucosidase enzyme in vitro
(Franco et al., 2013; Liu et al., 2014). Even though xanthohumol was the constituent that was shown 
to inhibit an enzyme, homogenous unfiltered hops was used as a treatment in this study rather than 
isolating xanthohumol, in case there were other active constituents. The use of hops to affect α­syn
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aggregation is a novel part of this investigation and the lab.  The final aim was to study the effects of 
hops on the aggregation of α­syn using an optimised protocol developed in the lab.
1.6 Aims and Hypotheses
Two major aims were chosen in this study.  The first was developing an in vitro ThT assay that could 
observe the formation of α­syn aggregates and to use this assay to test treatments that would 
prevent aggregate formation. The ThT assay alone will not resolve whether a treatment is preventing 
the formation of aggregates, but any changes in fluorescence will represent a possible interaction 
with protein aggregation.  The assay would be a preliminary step in discovering treatments that 
target the formation of α­syn oligomers in PD. Any treatments that reduce fluorescence could be 
studied and the mechanism of fluorescence reduction could be determined with confocal 
microscopy. The treatment used first was hops because research showed flavonoids affect the 
aggregation of α­syn and it was expected to have an inhibitory effect on fluorescence in the ThT 
assays (Stevens and Page, 2004; Liu et al., 2014).  The second major aim was to develop a 
preliminary behaviour assay using C. elegans and exposing them to α­syn. This study looked at 
behavioural changes to be able to test a greater number of subjects in a shorter period. Observing a 
decrease or increase in movement and bend speed was expected in C. elegans treated with α­syn 
oligomers because of studies showing the uptake of α­syn protein from the vagus nerve (Ulusoy et 
al., 2017).
2 Methods
2.1 Producing α­synuclein
The pET28a plasmid containing human α­syn sequence was used to express α­syn in the Escherichia 
coli strain BL21*(DE3). BL21 is a protease deficient strain of E. coli which results in fewer problems 
with protease activity when purifying proteins grown in them (Ratelade et al., 2009). The
engineered E. coli was a kind donation from Dr Agata Rekas (https://archive.ansto.gov.au/
ResearchHub/OurPeople/StaffProfiles/REKAS­AGATA), a protein chemist at the Australian Nuclear 
Science and Technology Organisation (ANSTO). Dr Rekas examined the α­syn by small angle x­ray 
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crystallography (Rekas et al., 2010) and determined the purity of the protein to be above 95% by 
SDS­PAGE and Mass spectrometry (Rekas et al., 2010; Pham et al., 2014).
The α­syn expressing E. coli was shaken overnight at 37°C in LB 5052 containing 50 µg/mL of 
kanamycin until solution turbidity reached an optical density range of 0.6 – 1.02. IPTG was not used 
to induce protein expression of α­syn as the protocol utilizes autoinduction (IPTG is commonly used 
to induce protein expression where genes are regulated by the lac operator). The whole LB solution 
was spun for 20 minutes at 6000g.  The supernatant was discarded, and the pellet was frozen at 20°C 
until the next step.
The pellet was resuspended in osmotic shock buffer (40% w/v sucrose in 30 mM Tris­HCl 2 
mM EDTA pH 7.2) and centrifuged at 6500g for 30 minutes.  The supernatant containing the proteins 
was collected and vortexed with 7.7 mM MgCl2• (H2O)6 in a final concentration of 20 mM Tris­HCl pH 
7.0. The new suspension was centrifuged for 20 minutes at 27000g at 4°C.  The supernatant was 
collected, and the pH was adjusted to 3.5, which caused other cellular proteins to precipitate, 
leaving α­syn soluble.  This suspension was centrifuged for 30 minutes at 27000g at 4°C and the 
supernatant was collected, and pH adjusted to 7.
Finally, the α­syn was purified using an FPLC anion exchange column (Nuvia Q, Cat No. 156­
0415, BioRad).  Alpha­syn was then dialysed against reverse osmosis (RO) H2O.  After dialysis the 
concentration of α­syn was determined using Fourier Transform Infrared (FTIR) spectroscopy (Direct 
Detect, Millipore).   The samples were portioned into 1 mg of protein, freeze dried and stored at ­
80°C until use. The lyophilization of α­syn was used in previous studies in which α­syn oligomers 
were produced (Kostka et al., 2008). In these studies, it was noted that lyophilised α­syn was 
reconstituted prior to use and that no protein was used more than once, thereby avoiding problems 
associated with repeated freeze thaw cycles. The purity of the α­syn was determined using SDS­
PAGE and western blot and was found to be greater than 98% pure.  Western blots were performed 
in the lab prior to this study and all bands appearing on the blot were identified by two different 
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commercially available antibodies against human alpha­synuclein (Mouse anti­alpha Synuclein 
antibody (abcam; ab27766); Rabbit anti­α­Synuclein antibody (Sigma; S3062­.2ML)).  Mouse anti­
alpha Synuclein antibody (abcam; ab27766) reacts with an epitope located in the region encoded by 
amino acids 115­122 of α­syn.  The rabbit polyclonal anti­α­Synuclein antibody was described as 
recognizing human and rat α­syn in the specification sheet provided by the manufacturer and the 
positive staining of α­syn in immunoblot experiments was specifically inhibited by an immunizing 
peptide. Samples were thawed and dissolved before use and no protein samples were used more 
than once.
Figure 2.1 The western blot above was run in 2019.  15μg of protein was loaded into wells 2 and 4. 10μg of protein was 
loaded into wells 1 and 3. The lanes contained the following: Lane 1) α­syn aggregated and prepared in 2019, lane 2) 2016 
α­syn (from 20190208 HP5 Sample 6), lane 3) 2019 α­syn, lane 4) α­syn aggregated and produced in 2016 (from 20190208 
HP5 Sample 6) and lane 5) 20μL Pre­stained Rainbow Mw Markers (Spectra Multicolour Broad Range Protein Ladder 
(Thermofisher; #26634)).
Protein purity was calculated using densitometry using BioRad Image Lab software (version 
5.2).  The background density of a suitably matched empty space on the gel was subtracted from 
each lane to normalise each lane. The background­corrected density of the protein band by the 
background­corrected density of the whole lane was divided and multiplied by 100 to get % purity 
(Stessl et al., 2009; 2017).  The majority of papers that use recombinant proteins use SDS­PAGE as a 
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measure of the purity of the protein after the purification steps, typically describing the purification 
steps as achieving a greater than 95% level of purity (e.g. Yanamandra et al., 2011; Magdeldin et al., 
2014; Wu et al., 2019).  The method used to establish the purity of the protein is standard across the 
literature and the level of purity reached is consistent with that reported by other papers (Huang et 
al., 2005; Manne et al., 2019; Wu et al., 2019).  Silver stain is an extremely sensitive method of 
protein detection on an SDS­PAGE gel, detecting protein content as little as 0.07 ng/mm2 (Oakley et 
al., 1980).  If all the bands detected by silver stain were shown to be α­syn, then it is reasonable to 
conclude that the purity of the α­syn produced is high.
2.2 Thioflavin T assays
The thioflavin T (ThT) assay was performed in a 96­well plate.  Assay was performed in triplicate 
using 150 μL of sample in each well.  Each well contained a 3­mm glass bead to assist with mixing the 
sample during the incubation unless otherwise noted.  The plate was incubated at 37°C for 169 
hours and fluorescence was read each hour using a FLUOstar Omega plate reader (BMG Labtech) 
with excitation of 440 nm and emission of 480 nm.  The plate was shaken at 500 rpm for two 
minutes immediately prior to each reading.  Each treatment contained a final concentration of 1 
mg/mL α­syn (concentration was chosen to keep aggregation time within 1 week; lower 
concentrations increase aggregation time (Kostka et al., 2008; Daturpalli et al., 2013)) in the ThT 
buffer (40 μM ThT in 0.1M PBS with 0.05% w/v thimerosal), with a 10% v/v of the treatment 
solution.  The solution was filtered with a 0.2­μm filter prior to adding the treatment and loading 
onto the plate.
Hops treatments were prepared in four different ways.  Firstly, raw cold hops extract was 
prepared by homogenizing 10 mg/mL of compressed hops pellets from a commercially available 
supplier (Ella Hops Pellets; craftbrewer.com.au) for two minutes in the ThT buffer at room 
temperature (~21°C) using a stick blender.  The unfiltered homogenate was then used as a 
treatment in the ThT assay.  A second treatment was prepared by filtering the raw cold hops extract 
used in treatment 1 through a 0.2­μm filter.  A third treatment was hops boiled at 10 mg/mL of the 
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same compressed hops pellets in ThT buffer for 10 minutes.  Any volume that was lost during boiling 
was replaced using RO water.  The raw homogenate from this process was referred to as Hot Hops
and was used as Treatment 3.  Lastly the active components from hops for use in brewing can be 
extracted from the plant material using liquid CO2.  A 1 mg/mL of the liquid CO2 extract purchased 
from a commercial source (CO2 Hops extract; Yakima Valley Hops) was used as Treatment 4.  Once 
the plate was loaded, the plate was sealed using Micro­seal 'B' PCR Plate Sealing Film (BioRad) to 
prevent evaporation of sample during incubation.
2.2.1 Analysis of ThT assays
The data from the plate reader was arbitrary fluorescence units over time.  Data was normalised in 
excel by setting the lowest value to zero.  The normalised data was exported to GraphPad Prism for 
analysis.  Four key features of the α­syn aggregation graphs were determined: maximal fluorescence, 
time to half maximal fluorescence, maximum reaction rate and the lag phase (time until the 
fluorescence became 5% greater than the blank sample).  Nonlinear regression was used to fit a 
curve to the data.  The maximal fluorescence was automatically calculated (the highest point of the 
curve).  The time to half maximal fluorescence and the lag phase were interpolated from the curve 
(finding the value of time for 0.5*max and 0.05*max).  The maximal reaction rate was determined by 
calculating the derivative of the curve and finding the peak value.  These four characteristics of the 
α­syn aggregation curve were used to compare the effects of different treatments on aggregation.
2.2.2 PAGE analysis of the ThT assays
After the ThT assays were completed, the well samples were stored at 4°C overnight.  The ThT assay 
samples were analysed using gel electrophoresis to observe the size of the aggregates.  PAGE gels 
(BioRad Mini­PROTEAN TGX Stain­Free Gels #456­8123) were run at 200 V for 45 min, stained using 
the Silver Stain Plus silver staining kit (Bio­Rad; ­#161­0449).  Samples were prepared using a loading 
buffer (250 mM Tris pH 6.8; 0.12% bromophenol blue; 40% v/v glycerol; 8% w/v SDS; 20% v/v β­
mercaptoethanol) and ran in a Tris glycine running buffer (25 mM Tris; 192 mM glycine; 0.1% w/v 
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SDS). The gels were imaged using Bio­Rad ChemiDoc MP System with Image Lab using similar steps 
described in section 2.1.
2.3 C. elegans
C. elegans strains were provided by the CGC, which is funded by NIH Office of Research 
Infrastructure Programs (P40 OD010440).  C. elegans were grown on nematode growth medium (see 
below for complete description) on 5.5 cm ventilated plates.  Unused plates (plates without worms) 
were sealed and stored at 4°C.  Plates containing C. elegans were stored at ambient room 
temperature.  To reduce rapid temperature fluctuation, plates were stored in a larger container with 
ventilation holes.  Naphthalene (moth ball) was placed in a 50­mL beaker and stored at the centre of 
the NGM plates at room temperature.  The naphthalene was used to prevent the infestation of 
mites, which was a common occurrence in the lab setting because of the ability of mites to crawl 
into plates. C. elegans treated with gaseous naphthalene increased the number of extra cells during 
exposure from the L4 larval state to adulthood, but when exposed only as adults, no significant 
difference was found (Kokel et al., 2006). This study found that any effects of naphthalene were
warranted to avoid mite infestation and all subjects would be exposed so any differences in 
behaviour should be caused by the unique treatments rather than naphthalene.
2.3.1 C. elegans growth media
Nematode growth media (NGM) is an agar formulation optimised to allow movement and 
development of C. elegans.  The final composition of NGM was 1.7% (w/v) agar, 50 mM NaCl, 0.25% 
(w/v) tryptone, 1 mM CaCl2, 5 µg/mL cholesterol (dissolved in EtOH), 25 mM KH2PO4 and 1 mM 
MgSO4.  Sodium chloride, agar and tryptone (in distilled H2O) were autoclaved before the 
cholesterol, magnesium sulphate, calcium chloride and phosphate buffer were added.  The NGM 
solution was cooled until ~60°C before being poured into 5.5 cm ventilated plates.  Plates were filled 
with 8 mL of NGM solution.
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The plates were left to dry at room temperature overnight and checked for fungal 
contamination the following day.  Sterile NGM plates were sealed and stored after an extra day of 
drying at 4°C (until the agar can easily be sliced).
M9 buffer (a buffer safe for C. elegans) was used as a solvent for all treatments added to C. 
elegans media.  The final composition of M9 buffer was 22 mM KH2PO4, 42 mM Na2HPO4 and 86 mM 
NaCl, which was autoclaved.  All solutions that would contact C. elegans were autoclaved or 
aseptically prepared using 0.2­µm filters.  All solutions and treatments were prepared before or 
during C. elegans breeding.
2.3.2 C. elegans nutrition
Two strains of bacteria (OP50­1 and α­syn overexpressing E. coli) were used to feed the C. elegans.  
Both strains of bacteria were grown using the same Lysogeny Broth, but with the addition of 
streptomycin (100 µg/mL) for OP50­1 and kanamycin (50 µg/mL) for the α­syn overexpressing E. coli.  
A small culture was prepared using bacteria from stock that had been stored at ­80°C.  The mini 
culture was grown on a shaking incubator overnight at 37°C and was used the following day to 
inoculate a larger preparation of 300 mL, which was shaken for 12 hours at 37°C.
After the incubation period, the resulting bacterial broth was stored at 4°C.  When the 
bacteria settled to the bottom of the flask, the excess LB was removed, and the bacteria was 
transferred into falcon tubes.  The falcon tubes were spun for 10 minutes at 2200 x g followed by the 
removal of remaining LB supernatant.  The bacterial pellet was resuspended in M9 buffer at a 
concentration of 100 mg/mL.
2.3.3 Preparing α­syn
Before beginning the C. elegans age synchronisation, freeze­dried α­syn (stored at ­80°C) was 
dissolved in M9 buffer to a concentration of 4 mg/mL.  The α­syn in M9 buffer was added to the 
wells of a 96­well plate in volumes of 150 μL together with a 3­mm glass bead.  In addition to making 
up α­syn in M9 buffer a sample of monomeric α­syn at the same concentration was made up in the 
ThT buffer and was run on the plate in triplicate to monitor the aggregation reaction.  As previously 
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the plates were then run at 37°C for 169 hours.  Fluorescence was measured each hour using a 
FLUOstar Omega plate reader at 440­nm excitation and 480­nm emission.  The plates were shaken at 
500 rpm for two minutes immediately prior to each reading.  After the plate run, the microplate was 
removed from the reader and stored at 4°C until use.
2.3.4 C. elegans breeding
Egg­laying adults of C. elegans were prepared by first plating the C. elegans in breeding plates and 
allowing them to multiply.  Worms were given 5­6 days to breed and were starved by not adding any 
more bacteria. Chunks of agar from the starved breeding plates were then inverted onto fresh 
plates and grown for an additional 48 hours.
Different strains required different times of incubation to ensure all strains contained a 
maximal number of egg laying adults at the same time; some strains were prepared earlier than 
others.  Three different strains were used in this study.  The first was the wild type N2 (C. elegans
wild isolate var Bristol provided by the CGC, which is funded by NIH Office of Research Infrastructure 
Programs (P40 OD010440)).  The second strain was DDP1 (uonEx1 [unc­54::alpha­synuclein::CFP + 
unc­54::alpha­synuclein::YFP(Venus)]; also acquired from the CGC), a C. elegans strain 
overexpressing a­synuclein in its muscle cells, and DDP2 (uonEx2 [unc­54::CFP::YFP(Venus)]; 
acquired from the CGC), a strain containing the same plasmid without the overexpression.  DDP1 
strains were grown 12 hours prior to the N2 and DDP2 strains for a total of 60 hours because of their 
observed developmental delay.   Breeding the worms twice worked to partially synchronise the 
growth of egg­laying adult C. elegans to maximise the number of eggs produced for the hatch 
synchronisation steps that follow.
An important aspect of C. elegans growth is temperature regulation and maintaining even 
ambient temperature.  C. elegans were incubated in an insulated container stored in a temperature­
controlled room with a digital thermometer to track temperature change.  The ideal temperature 
range for C. elegans is between 16°C and 24°C.  The C. elegans grow and reproduce more slowly on 
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the cooler side of this range and much more rapidly on the warmer side of this range.  In this study, 
the average temperature was 23°C.
Once the C. elegans reached the egg laying stage, their eggs were harvested using the 
following steps.  The C. elegans were rinsed off their plates, spun down and washed with water.  
Bleach (hypochlorite) was used to lyse all the worms, a process that leaves their eggs intact.  After 
several washes in M9 buffer to neutralise the bleach, the eggs were spun down a final time and 
resuspended in M9 buffer.  They were rocked overnight in 50 mL centrifuge tubes with at least 50% 
empty space in the incubation tube to allow sufficient aeration.
Overnight, the eggs hatched at different times according to the developmental stage of the 
eggs, however subsequent growth of the worms were halted by the absence of food resulting in an 
age synchronised batch of worms.  The worms were counted and diluted to 90 worms/mL before 
adding the treatments.  A total of 200 µL was added to each plate bringing the total plate population 
to 10­20 worms.
2.3.5 Treating the C. elegans
The age synchronised C. elegans hatchling plates were treated with four different treatments and 
grown with two different types of E. coli as food.  The two bacterial strains (OP50­1 and α­syn 
expressing E. coli) were added to separate diluted hatchling solutions then the inoculated hatchling 
solutions were added to pre­treated NGM plates with one of the four treatments described below.  
The C. elegans were incubated for 24 hours before adding FUDR to sterilise the worms and prevent 
new eggs from hatching.  All the worms at this point should be approximately the same size and age 
with little variation.
The control treatment was M9 buffer, the second treatment was aggregated α­syn dissolved 
in M9 buffer to see if the worms could take in the protein. The third treatment was aggregated α­
syn with hops in M9 buffer to see if hops reduced any effects of aggregated α­syn. The final 
treatment was hops dissolved in M9 buffer to see if the hops had any effects on the worms.  The 
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OP50­1 worms were denoted normal worms and the treatment was indicated with an O, e.g. worms 
fed OP50­1 bacteria in M9 buffer were N2 OMM, worms fed OP50­1 bacteria in M9 buffer to which 
had been added aggregated α­syn were denoted Treatment N2 OAM etc.  Worms that were fed α­
syn expressing E. coli were indicated with an α symbol, so worms fed α­syn expressing E. coli in M9 
buffer were denoted N2 EMM.  Worms that were fed α­syn expressing E. coli in M9 buffer that 
contained 4 mg/mL aggregated α­syn were denoted N2 EAM, etc (See Table 1 for full list of C. 
elegans treatment groups). The worm plates were incubated at an ambient room temperature in an 
insulated container for 48 hours before recording.
Table 1 Behavioural treatments used on worm plates
Strain Food Amount of 
food (mg 
in 50 µL)
a­synuclein 
aggregated 
over time
Amount of 
a­synuclein 
(µg in 50 µL)
Counter 
treatment
Amount of 
hops (µg 
in 11.11 
µL)
Number of 
plates
N2 OP50­1 5 M9 0 M9 0 2
Hops 5.55 2
a­synuclein 
aggregated 
over time
200 M9 0 2
Hops 5.55 2
E. coli a­
syn
5 M9 0 M9 0 2
Hops 5.55 2
a­synuclein 
aggregated 
over time
200 M9 0 2
Hops 5.55 2
DDP1 OP50­1 5 M9 0 M9 0 2
Hops 5.55 2
a­synuclein 
aggregated 
over time
200 M9 0 2
Hops 5.55 2
DDP2 OP50­1 5 M9 0 M9 0 2
Hops 5.55 2
a­synuclein 
aggregated 
over time
200 M9 0 2
Hops 5.55 2
2.4 Behaviour analysis
2.4.1 Recording
After the worms were treated, and adults were moving around on the NGM plates, the NGM plates 
were recorded.  Before recording the plates, the plates were removed from the insulated container 
and were allowed 10 minutes to acclimate to the new temperature and lighting.  The plates were 
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recorded 48 hours after treatment.  Plates were recorded one at a time with the field of view of the 
microscope focused on different regions of the plate for each recording.  Worms were recorded with 
an eyepiece camera.  Recordings were made through the 4x objective of a benchtop microscope.  
The videos recorded were set to a manual exposure of 112, 30 ms exposure time and 1.00 gain.  The 
videos were 872 x 654 px, RGB format and set to grayscale. Videos were recorded for 60 seconds.
2.4.2 Video Analysis
ImageJ Fiji with the wrmtrck plugin was used with a macro to complete analysis in batch.  For the 
wrmtrck plugin to work, the following steps were done to make videos compatible.  Videos were 
uploaded in an uncompressed AVI format.  The videos were then converted to 8­bit grayscale.  The 
grayscale footage was then converted to binary black and white images using a threshold 
(MaxEntropy setting under AutoThreshold) where a certain level of grey colour was converted to 
white and darker shades of grey were converted to black, making any moving objects black with the 
background white.  ImageJ was used to get an average background image, which was subtracted 
from all the images in the video, leaving behind objects in motion.  Once the video was prepared, 
the wrmtrck plugin was used.
The plugin requires specific settings to be able to detect moving objects.  The first setting is 
the estimated size of the moving object (C. elegans) in pixels with a minimum (300 px) and maximum 
(20000 px) range.  The next field was the estimated maximum velocity of the worm (10 px/s).  The 
last important field was the bend threshold (setting 2, explained in the next paragraph), which is a 
method of bend calculation.  The other fields do not affect the analysis of the video, they only affect 
the presentation of analysis.
The data collected from the video was length, distance, #frames, time, maximum speed, 
average speed, body lengths per second (calculated by dividing the Length of the track by 
Perimeter/2 and the time in seconds).  Not all this data was used to compare behaviour between 
treatments but were used instead to remove artefacts from the data.  For example, any objects 
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detected for less than 5 frames per second were removed from the data.  This data was imported in 
to excel for processing.
As previously mentioned, the data from all the C. elegans videos were screened for artefacts 
by removing objects tracked for less than 5 frames per second.  The data was organised for statistical 
analysis.  The data was also tested for normal distribution using box plots to determine the statistical 
test that would be used.  A high percentage of the data did not follow normal distribution.
2.4.3 Statistical Analysis of video data
Since the data did not show normal distribution, the non­parametric Kruskal–Wallis one­way analysis 
of variance test was used to compare multiple sets of data together with Bonferroni correction.  
After determining any significance between multiple sets of data, the data was compared 
individually using the non­parametric t­test equivalent, the Mann Whitney U test.
2.5 Life span assay
2.5.1 Assay preparation
A life span assay was repeated multiple times using a 96­well plate (Solis and Petrascheck, 2011). 
After age synchronising the worms, an average of 10 worms were added to each well of a microplate 
(the bottom of the microplate was marked into four equal quadrants for future counting). The same 
treatments used in the behavioural analysis were used in the life span assay. Instead of NGM, the 
worms were kept in S­complete because of the small size of the wells.
The final media, S­complete is a liquid media that allows C. elegans to move and develop. S­
media is useful when growing C. elegans in 96­well plates because it is easier to dispense and 
maintain in small volumes. S­complete was prepared by first making a solution called S­basal 
medium (50 mM potassium phosphate, pH 6.0, 100 mM NaCl with 1 mL of 5 mg/mL cholesterol 
added after autoclaving). A trace metal solution, another ingredient in S­complete, was prepared by 
adding 1.86 g Na2EDTA, 0.69 g FeSO4 ·7H2O, 0.20 g MnCl2 · 4H2O, 0.29 g ZnSO4 ·7H2O and 0.016 g 
CuSO4 to a final volume of 1 L in deionised water; the solution was autoclaved and stored in the 
dark.  Potassium citrate was also necessary for the preparation of S­complete; 268.8 g tripotassium 
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citrate, 26.3 citric acid monohydrate, pH 6.0 and a final volume of 1 L deionised water.  All the 
solutions prepared were autoclaved before being combined.  The final composition of S­complete 
was 977 mL S­basal, 10 mL 1M potassium citrate, 10 mL Trace metals solution, 3 mL 1M CaCl2 and 3 
mL 1M MgSO4 (Solis and Petrascheck, 2011).
2.5.2 Assay observation
The wells were counted both daily and intermittently using a microscope for living and dead worms.  
Wells were counted in quadrants to minimise double counting.  Worms that did not move when the 
plate was tapped were counted as dead.  Moving worms were counted as alive.
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3 Results – In Vitro
The work described in this thesis was performed in two parts, part one was performed in vitro and 
part two was performed in vivo.  The principal aim of this study was to develop a screening system 
to investigate potential therapeutic agents for their ability to modify α­syn aggregation, one of the 
principle pathologies thought to underlie the development and progression of PD.  The in vitro 
experiments allow rapid screening of agents to determine which can alter the rate of α­syn 
aggregation.  Having identified these potential therapeutics, the second part of this study was to 
develop an invertebrate in vivo model which would allow rapid testing of any identified agent in a 
living organism.
3.1 Effects of Hops on α­syn aggregation
3.1.1 Α­syn aggregation fluorescence curves
The goal in this experiment was to determine whether hops has any effect on α­syn aggregation.  
These experiments were performed in vitro.  The first step was to observe α­syn aggregation without 
hops.
Figure 3.1 The graph above is an average of three independent experiments (n=3) in which aggregation of 1 mg/mL α­syn 
was monitored over 169 hours at 37°C.  Each experiment was performed in triplicate.  Error bars are standard error of mean 
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(SEM).  Measurements were taken every hour after being shaken at 500 rpm for two minutes with an excitation of 440 nm 
and an emission of 480 nm.  The data for each run was normalised before analysis.
After completing a ThT assay, four key points were analysed in all treatments.  Key points to note on 
this graph are A) the maximum fluorescence, B) the time when fluorescence is half of max, C) the 
peak rate and D) the lag phase, which was the time when fluorescence was 5% of maximum 
fluorescence.  The lag phase represents the time when β­sheets initially form and fluorescence can 
be detected.  The peak rate is when β­sheets should be forming at the fastest rate and the maximum 
fluorescence represents the plateau of β­sheet formation.
The maximum fluorescence for α­syn at a concentration of 1 mg/mL was 30794, which 
occurred at 169 hours.  The fluorescence was half of maximum (15397 at 86.8 hours.  The peak rate 
(fastest increase in fluorescence) was at 76.5 hours which happened before half max.  Finally, the lag 
phase was at 44.4 hours.  These four values were compared to the values in ThT assays containing α­
syn aggregated with hops.
3.1.2 Effects of hops prepared at room temperature on α­synuclein aggregation
ThT assays were performed using unfiltered hops prepared at room temperature to detect any 
constituents that may cause changes in fluorescence.  The following graphs present fluorescence 
data using hops homogenate prepared at room temperature.
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Figure 3.2 The graph above contains the same α­syn curve in Figure 3.1 compared with the addition of 1 mg/mL α­syn
aggregated with a final concentration of 0.0125% w/v hops prepared at 22°C (n=3).  The error bars are SEM. Microplates 
were incubated at 37°C for 169 hours, with measurements taken every hour after being shaken at 500 rpm for two minutes 
with an excitation of 440 nm and an emission of 480 nm.
The first treatment added to α­syn in the ThT assay was 0.0125% w/v. Adding hops to the α­syn 
samples to a final concentration of 0.0125% w/v, resulted in a greater than 2.6­fold decrease in 
maximal fluorescence compared to the maximum fluorescence of α­syn.  The half­max and the lag 
phase fluorescence were also 2.6­fold greater.  The α­syn solution’s half­max was 3.22 hours earlier 
than the 0.0125% w/v hops sample, 3.7% earlier than the α­syn.  The hops solution’s lag phase was 
4.73 hours after the α­syn solution.  The time to hit peak rate was 1 hour earlier in the α­syn
solution.
The standard error of mean for the hops curve was close to 50% of the fluorescence value.  
There was a greater amount of variance in the hops solution, whereas the SEM for α­syn was close 
to 6­10% of the fluorescence value and fluorescence across different assay runs were consistently 
the same.  The concentration of hops was increased to observe the impact on fluorescence or 
aggregation.
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Figure 3.3 The graph above shows aggregated α­syn and 3 different concentrations of hops prepared at room temperature
(0.025­0.1% w/v hops in α­syn solution n=3).  The error bars are SEM. The error bars are SEM. Microplates were incubated
at 37°C for 169 hours, with measurements taken every hour after being shaken at 500 rpm for two minutes with an 
excitation of 440 nm and an emission of 480 nm.
Increasing the concentration of hops prepared at room temperature further decreased the 
fluorescence readings compared to the α­syn sample. A concentration of 0.1% w/v hops was 
enough to reduce maximum fluorescence to less than 1.5% of the α­syn sample. The standard error 
of mean also decreased for every increase in hops concentration because there was less variance in
fluorescence for the 0.05­0.1% w/v hops between assay runs. To highlight the fold difference 
between the key phases, the maximum fluorescence of all dilutions was presented in Figure 3.4.
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Figure 3.4 This graph shows the maximum fluorescence of α­syn aggregation with different concentrations of hops
prepared at room temperature from the samples graphed in Figure 3.2 and Figure 3.3.
Each time the concentration of hops was doubled the maximum fluorescence decreased.  From 0% 
w/v to 0.0125% w/v hops, the fluorescence decreased 2.60­fold.  From the 0.0125% w/v to 0.025% 
w/v, the fluorescence decreased 1.89­fold.  From 0.025% w/v to 0.05% w/v, the fluorescence 
decreased by 2.80­fold.  From 0.05% w/v of hops to 0.1% w/v, the fluorescence decreased by 3.89­
fold. Adding 0.1% w/v hops caused a 53­fold decrease in maximum fluorescence compared to α­syn 
alone.
Figure 3.5 The peak rate of fluorescence growth (the point of inflection) of the curves in Figure 3.1 and Figure 3.2.
The peak rate of aggregation in Figure 3.5, the point of inflection on the curve had a similar fold 
difference between each concentration as the maximum fluorescence.  From 0% w/v to 0.0125% 
w/v hops, the peak rate decreased 2.10­fold.  From the 0.0125% w/v to 0.025% w/v, the peak rate 
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decreased 1.89­fold.  From 0.025% w/v to 0.05% w/v, the fluorescence decreased by 4.72­fold.  
From 0.05% w/v of hops to 0.1% w/v, the fluorescence decreased by 14.73­fold.  This means the 
fluorescence curves were proportionally smaller than each other due to the higher concentrations of 
hops.  The difference in time for each fluorescence key phase was graphed below to determine if the 
curves were not only proportionally smaller, but also had an earlier lag phase.
Figure 3.6 The time of each phase: half max time and lag phase (time to reach 5% of max) for the different concentrations 
of hops prepared at room temperature were compared.
The time to reach each phase increased as the concentration of hops increased, meaning the curves 
shifted to the right.  The curves are proportional in shape, but the size and position on the timeline is 
different depending on the concentration.  Hops could either be competitively binding to ThT, 
binding to α­syn monomers preventing aggregates from forming or even changing the shape of 
aggregates to no longer contain β­sheets.  To see how the hops influenced fluorescence in the 
assays, the samples were run on polyacrylamide gels.
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Figure 3.7 The samples used in the ThT assays in Figure 3.2 and Figure 3.3 were analysed using gel electrophoresis.  The 
concentrations of hops were the final concentrations in the assay and not in the gel.  The gel (BioRad Mini­PROTEAN TGX 
Stain­Free Gels #456­8123) above was run at 200 V for 30 min, stained using Bio­Rad Silver Stain Plus #161­0449 and were 
imaged using Bio­Rad ChemiDoc MP System with Image Lab. Total exposure time to white epi illumination was 0.113 s.
Samples were taken after a microplate run, prepared using 4X loading buffer to 1 µL sample and were diluted using Tris 
glycine running buffer. All gel samples contained ~1 µg of α­syn protein dissolved in ThT buffer. Molecular weights were 
calculated using Bio­Rad Precision Plus and Linear (semi­log) regression. Three independent replicates of this gel were 
performed.
SDS PAGE were run to determine the presence of α­syn after exposure to hops and after a week of 
being incubated at 37°C. Although SDS PAGE is not as conclusive as a western blot when checking 
for specific protein presence, previous western blots were run by the lab to determine the presence 
of α­syn, thereafter, any bands in the 14­16 kDa region were determined to be α­syn in SDS PAGE.
Previous research demonstrated that some α­syn aggregates were SDS­resistant when exposed to 
dopamine, which could be possible with hops as well (Cappai et al., 2005).  The gels were also run to 
see if any protein aggregates were preserved even after exposure to SDS, a detergent used to break 
bonds and denature proteins to allow size separation and β­mercaptoethanol, used to break 
disulphide bonds.
There were four notable band regions in Figure 3.7, A­D. The average molecular weights of 
these four bands were 164.76 kDa (A), 66.97 kDa (B), 40.92 kDa (C) and 14.72 kDa (D).  Increased 
concentrations of hops caused more smearing and increased staining intensity in the higher 
molecular weights.  Running hops without α­syn protein in lane 6 resulted in light smearing in line 
with arrow A and D. The light bands found in lane 7 and 6 (hops only) are also found in lane 1 with 
greater intensity, meaning there may have been some lane leakage from the lanes containing α­syn 
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into the hops only lanes. The different adjusted volume of band intensity (arbitrary unit of 
measurement) was compared for the 4 molecular weights.
Figure 3.8 Intensity of bands with molecular weights 164.76 kDa (A), 66.97 kDa (B), 40.92 kDa (C) and 14.72 kDa (D) of 1 µg 
α­syn and different concentrations of hops.  These bands can be seen Figure 3.7 to the right of the arrows.
The intensity of the 164.76 kDa band decreased from 0% w/v hops to 0.025% w/v hops and then 
increased again after 0.05% w/v to 0.1% w/v.  The intensity of the 66.97 kDa band decreased from 
0% w/v hops to 0.025% w/v hops.  Bands were undetected with molecular weight 66.97 kDa in 
solutions with 0.05 and 0.1% w/v.  The intensity of the 40.92 kDa band increased from 0% w/v hops
and peaked at 0.0125% w/v hops.  From 0.025 to 0.1% w/v band intensity dropped.  The intensity of 
the 14.72 kDa band decreased from 0% w/v hops to 0.0125% w/v hops.  From 0.025 to 0.1% w/v 
band intensity dropped by 4­fold.  The 0.05% w/v hops sample bands showed similar results with the 
darkest stain occurring in the highest molecular weight with lesser intensity in the lower molecular 
weights.  The lower concentrations of hops resulted in the darkest bands being in the monomeric 
region of 14.72 kDa and 40.92 kDa and lighter staining in 66.97 kDa.
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Figure 3.9 Total adjusted volume of band intensity for lanes 1­5 in Figure 3.7.
Since all samples have ~1 µg of α­syn, the protein content or band intensities in each lane should 
add up to a similar total.  Total adjusted volume of band intensity for concentrations 0­0.025% w/v 
were an average of 3­fold greater than 0.05 and 0.1% w/v, meaning that there may be some protein 
loss in the lanes containing 0.05 and 0.1% w/v.
3.1.3 Effects of boiled hops on aggregation
In the results above, hops was prepared at room temperature without filtration.  Different methods 
of extraction were tested to find the best method of preparing hops to reduce α­syn aggregation.
CO2 extracted hops could not be analysed because of the high turbidity of the solution upon 
preparation and during the 169 hour incubation in the plate reader.  The ThT assay results of the 
hops prepared by boiling are presented next.  Hops was boiled for 10 minutes and evaporated water 
was replaced and cooled before being added as a treatment in the ThT assay.
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Figure 3.10 The graph above shows aggregated α­syn and 4 dilutions of hops prepared by boiling at 100°C for 10 minutes 
(0.0125­0.1% w/v hops in α­syn solution n=3).  The error bars are SEM. Microplates were incubated at 37°C for 169 hours, 
with measurements taken every hour after being shaken at 500 rpm for two minutes with an excitation of 440 nm and an 
emission of 480 nm.
The error bars for each concentration of hops were less than 10% of fluorescence and represent 
minimal variance of fluorescence across assay repetitions.  The 4 phases of the different 
concentrations of boiled hops treatments were analysed below starting with maximum fluorescence.
Figure 3.11 The maximum fluorescence for each dilution of hops prepared by boiling at 100°C for 10 minutes from the 
samples graphed in Figure 3.10.
The maximum fluorescence change between the dilutions at 100°C have a similar change to the hops
prepared at room temperature.  The change in maximum fluorescence was increasingly smaller with 
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each increase in hops concentration.  The maximum fluorescence of 1 mg/mL α­syn was 2.8­fold 
greater than 0.0125% w/v hops, 5­fold greater than 0.025% w/v hops, 10­fold greater than 0.05% 
w/v hops and 71­fold greater than 0.1% w/v hops.  The peak rate of fluorescence of the different 
hops dilutions was compared next.
Figure 3.12 The peak rate of fluorescence for each dilution of hops prepared by boiling at 100°C for 10 minutes from the 
samples graphed in Figure 3.10.
The peak rate of fluorescence for 1 mg/mL of α­syn in Figure 3.12 was 2.3­fold greater than 0.0125% 
w/v hops, 4.2­fold greater than 0.025% w/v hops, 12­fold greater than 0.05% w/v hops and 119­fold 
greater than 0.1% w/v hops. Time to reach half max and lag phase were also compared.
Figure 3.13 The time of each phase: half max time and lag phase (time to reach 5% of max) for the different concentrations 
of hops prepared by boiling were compared.
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Similar to the hops prepared at room temperature, every increase in hops concentration led to an 
increased delay to reach a phase in Figure 3.13.  The lag phase could not be calculated in 0.1% w/v 
hops when prepared at room temperature or by boiling.  To see the effect of hops on aggregate size, 
samples were analysed using gel electrophoresis.
Figure 3.14 The samples used in the ThT assays in Figure 3.10 were analysed using gel electrophoresis.  The concentrations 
of hops were the final concentrations in the assay and not in the gel.  The gel (BioRad Mini­PROTEAN TGX Stain­Free Gels 
#456­8123) above was run at 200 V for 30 min, stained using Bio­Rad Silver Stain Plus #161­0449 and were imaged using 
Bio­Rad ChemiDoc MP System with Image Lab. Total exposure time to white epi illumination was 0.116 s. Samples were 
taken after a microplate run, prepared using 4X loading buffer to sample and were diluted using Tris glycine running buffer.
All gel samples contained ~1 µg of α­syn protein dissolved in ThT buffer. Lane 5 in the figure above was originally lane 1 in 
the gel; other lanes were removed because the treatments were not analysed in this study. Molecular weights were 
calculated using Bio­Rad Precision Plus and Linear (semi­log) regression.
The samples from the ThT assays were analysed to show the effect of hops on aggregation.  There 
were four notable band regions stained in the gel in Figure 3.14, A­D. The average molecular 
weights of these four bands were 164.76 kDa (A), 66.97 kDa (B), 40.92 kDa (C) and 14.72 kDa (D).  
Increased concentrations of hops caused more smearing.
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Figure 3.15 Intensity of bands with molecular weights 166.525 kDa (A), 72.45 kDa (B), 43.0 kDa (C) and 17.0 kDa (D) of 1 µg 
α­syn and different concentrations of hops.  These bands can be seen Figure 3.14 to the right of the arrows.
The intensity of the 166.525 kDa band decreased from 0% w/v hops to 0.025% w/v hops and then 
increased again after 0.025% w/v to 0.05% w/v.  The intensity of the 66.97 kDa band decreased from 
0% w/v hops to 0.025% w/v hops.  Bands were undetected with molecular weight 72.45 kDa in 
solutions with 0.0125 and 0% w/v.  The intensity of the 43 kDa band increased from 0% w/v hops
and peaked at 0.0125% w/v hops.  From 0.025 to 0.05% w/v band intensity dropped.  The intensity 
of the 17 kDa band decreased from 0% w/v hops to 0.0125% w/v hops.  From 0.025 to 0.05% w/v 
band intensity dropped by 20%.  In the 0.05% w/v hops sample, the darkest bands were in the 
166.525 and 17 kDa regions and lightest in the 40.92 and 66.97 kDa regions.  The 0.05% w/v hops
sample bands showed similar results with the darkest stain occurring in the highest molecular 
weight with lesser intensity in the lower molecular weights.  The lower concentrations of hops
resulted in the darkest bands being in the monomeric region of 17 kDa and 43 kDa and lighter 
staining in 72.45 kDa.
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Figure 3.16 Total adjusted volume of band intensity for lanes 1­5 in Figure 3.14.
In Figure 3.16, all bands were totalled in each lane to calculate the total protein content collected 
from the 1 µL ThT assay sample.  Total adjusted volume of band intensity for concentrations 0.025­
0.05% w/v were an average of 35% greater than 0% w/v intensity.
3.1.4 Comparing the effects hops prepared at different temperature on aggregation
Figure 3.17 The maximum fluorescence for different concentrations of hops prepared at different temperatures.
The effect on aggregation of the two different methods of preparing hops were compared.  The 
maximum fluorescence was nearly identical for hops prepared at different temperatures.  The 
difference between preparation temperatures occurred at 0.0125 and 0.05% w/v of hops.  The 
difference occurring at 0.0125% w/v of hops might be due to the higher variance in the sample 
prepared at room temperature.
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Figure 3.18 The peak rate of fluorescence for different concentrations of hops prepared at different temperatures.
The peak rate of fluorescence between hops preparations was also similar.  The final comparison of 
the time to reach is presented next.
Figure 3.19 The time of each phase: half max time and lag phase (time to reach 5% of max) for the different concentrations 
of hops prepared at different temperatures.
The time to reach either phase was similar in concentrations 0.0125­0.025 % w/v.  However, the lag 
phase was earlier in 0.1% w/v boiled hops than the hops prepared at room temperature and the half 
max could not be calculated for either preparation.
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4 Discussion – In Vitro
The in vitro part of this study was done to identify whether hops had any effect on α­syn aggregation 
and thereby to identify whether hops was worth pursuing as a potential therapeutic agent for the 
treatment of the α­syn pathology associated with PD progression.  The effects analysed in this part 
of the study were to look for any changes in maximum fluorescence, the time before onset of 
aggregation, changes in the rate of aggregation and the time to reach half of maximum fluorescence.  
Briefly, the principle findings of this study were that the addition of a raw homogenate solution of 
hops resulted in a dramatic, concentration dependent decrease in fluorescence over the course of a 
week compared to monomeric α­syn alone as determined using a ThT assay.  Several methods of 
preparation of hops were investigated, two of which demonstrated a similar degree of inhibition of 
fluorescence. What this tells us about the potential effect of hops on the aggregation of α­syn will 
be examined here.
4.1 Technical considerations of ThT assay
The first step that was necessary to evaluate compounds that may affect α­syn aggregation was
selecting a method in order to measure aggregation.  The method chosen for this study was the ThT
assay. ThT is a dye which becomes fluorescent when it binds to proteins with a β­sheet 
conformation (Voropai and Samtsov, 2003; Krebs et al., 2005). The dye is thought to intercalate 
between side chains of the amyloid fibril, parallel to the fibril axis (Krebs et al., 2005).  The use of the 
ThT assay in order to monitor α­syn aggregation is well established and used in a number of studies 
(Krebs et al., 2005; Stsiapura et al., 2008; Wolfe et al., 2010; Alavez et al., 2011).  As described in 
section 3.1.1, the change in fluorescence over time of α­syn in the presence of ThT when plotted, 
typically forms a sigmoidal curve consisting of an initial lag phase in which fluorescence dramatically 
increases and a final plateau phase in which no further increase in fluorescence is observed (see 
Figure 3.1).
When the aggregation of an amyloid protein is examined using the ThT assay, any treatment 
which reduces the amount of fluorescence is interpreted as a reduction in the amount of β­sheet 
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containing aggregates forming (Daturpalli et al., 2013).  However, there are three possibilities that a 
given treatment may result in a decreased level of fluorescence.  1) There may be a decreased level 
of aggregation and thus β­sheet formation resulting in a decreased level of fluorescence, 2) the 
treatment may be competing with the ThT for the ThT binding sites on the β­sheets, thereby 
reducing the amount of ThT binding and the level of fluorescence observed but not necessarily 
reducing the amount of aggregation of α­syn, and 3) that the amyloid protein being examined may 
be broken down or altered by the treatment and thus not cable of forming β­sheets.  Because of the 
chance of these three possible outcomes, the second step in this study was to measure the size of 
the protein after aggregation in thioflavin T, using size separation with polyacrylamide gel 
electrophoresis.  These two techniques together were used to test treatments against aggregation in 
an in vitro model by measuring their effects on α­syn aggregation.
Another technical consideration of the ThT assays is the impracticability of using 
physiological concentrations, found to be 0.8 to 16.2 pg/μl (8x10­7 to 1.6x10­5 mg/mL) (Mollenhauer 
et al., 2008).  Using the minute concentrations found in the human body would cause aggregation to 
take months or years when proportionally compared to prior studies measuring aggregation (Kostka 
et al., 2008; Giehm et al., 2011; Daturpalli et al., 2013).  Although physiological concentrations would 
be ideal in an assay to increase relevance to PD pathology, the small concentrations are impractical.
The average shape of the α­syn aggregation curve had a lag phase in the first 48 hours. The 
α­syn was most likely forming small oligomers in this phase, undetected by ThT fluorescence (Leung 
et al., 2015).  After this phase, the curve increased exponentially, reaching a maximum rate after 
three days, where the aggregates were forming fibrillar β­sheets.  In the final phase after the 
fluorescence rate peaked, the curve plateaued, which means the aggregates were mostly bound to 
each other with fewer small aggregates left unbound.  In Figure 4.1 below, researchers observed a 
single fibril’s growth using total internal reflection fluorescence microscopy stained with ThT.
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Figure 4.1 Direct observation of α­syn fibril growth by total internal reflection fluorescence microscopy (TIRFM).  Time series 
of TIRFM images of a solution (160 μM) of monomeric α­syn in the presence of 15 μg/ml seeds and 7 μM ThT.  Excitation of 
ThT fluorescence with a 405­nm laser, filtering of fluorescence emission through a 450/50 bandpass filter.  The scale bar 
represents 2 μm (Wördehoff et al., 2015).
The figure above demonstrates the effectiveness of using ThT to track the aggregation process and 
helps visualise what is most likely occurring in the ThT assays (Wördehoff et al., 2015).  The speed 
and simplicity of ThT assays allow multiple treatment candidates to be tested and to further validate 
findings another in vivo assay was performed.
The treatment tested in this study was hops, an ingredient used to brew beer.  Hops was 
chosen because of its high flavonoid content and the evidence suggesting that flavonoids may affect
α­syn aggregation (Liu et al., 2014). Moreover, hops was also found to reduce memory impairment 
in mouse Alzheimer model (Sasaoka et al., 2014).  Thus, the flavonoid content and the potential 
therapeutic effect in another neurodegenerative disease makes hops an ideal first candidate for this 
study.
4.2 Alpha­synuclein ThT assay
The first ThT assay analysed was α­syn without additional treatments.  The α­syn was analysed at 1 
mg/mL because the maximum fluorescence was in the measurable range of the spectrophotometer
and was also generated aggregation in vitro in a reasonable amount of time (Giehm et al., 2010).  
The hops­treated α­syn assays were compared to the average fluorescence rate of this first
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untreated α­syn aggregation to detect any possible therapeutic effects by comparing maximum 
fluorescence, peak fluorescence rate, time to half max and the lag phase (time to reach 5% of max).
The different parts of the fluorescence curve will be examined in chronological order, 
starting with the lag phase.  In another study, 50 µM or 0.7 mg/mL of α­syn with 50 µM ThT agitated 
with a 3­mm glass bead in a 96­well microplate showed a lag phase at 30­40 hours (seen in Figure 
4.2 below) (Coelho­Cerqueira et al., 2014), which was close to the lag phase in this study, an average 
of 44.5 hours.
Figure 4.2 ThT (50 µM) was added at different stages (0, 24 or 48 h) to a solution of 50 µM a­syn monomer in 10 mM NaPB, 
pH 7.5. The a­syn aggregation was carried out in a 96­well plate at 37 °C and agitation in the presence of a 3­mm glass 
bead per well (Coelho­Cerqueira et al., 2014).
The experimental setups were quite similar in both studies with the key differences in a 70% 
concentration of protein and 20% increased concentration of ThT compared to this study, the 
fluorescence curves reflected these changes. Despite this, the results were quite similar, suggesting 
that the results reported for α­syn alone in a ThT assay in our study are keeping with what was 
reported previously in the literature.
Depending on the method of agitation, the fluorescence curve can increase at a faster rate.  
Small changes to pH or salt content can also increase the aggregation rate (Hoyer et al., 2002). In 
Figure 4.3 below, ultrasonication was used in another study to aggregate α­syn resulting in higher 
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peak rate.  The peak fluorescence rate was greater and the maximum fluorescence occurred at 6­7 
hours as opposed to 169 hours in this study.
Figure 4.3 Time­dependent changes in ThT fluorescence under various conditions of ultrasonication: cycles of 
ultrasonication for 9 min with quiescence for 1 min with a high (red) or low (blue) ultrasonic amplitude or cycles of 
ultrasonication for 4 min with quiescence for 1 min with a high (orange) or low (cyan) amplitude (Noda et al., 2016).
The peak rate and maximum fluorescence in a study using agitation to aggregate 70 µM (~1 mg/mL)
α­syn resulted in values closer to the one observed in this study.  After α­syn was shaken in a plate 
reader for over 3 days at 37°C, the peak rate occurred between 40 and 50 hours and the maximum 
fluorescence after 110 hours seen in Figure 4.4 (Daturpalli et al., 2013). Daturpalli et al. (2013) also 
took transmission electron microscopy (TEM) images before and after the ThT assays and showed 
that α­syn was forming fibrils.
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Figure 4.4 The red line represents fluorescence of 70 µM or ~1 mg/mL α­synuclein with 70 µM ThT shaken for 3 days
(Daturpalli et al., 2013).
The ThT assays performed in this study were consistent with those found in the literature with minor 
differences caused by variations in methodology. It is noteworthy that there was less variation 
between replicates in the present study compared with the previously reported studies, suggesting 
good consistent execution of the assay.  The untreated α­syn aggregation served as the control for 
the hops treatments.  The effects of hops on the different phases of the fluorescence curve were 
compared to detect whether there was an effect on aggregation.
4.3 Hops effects on aggregation
Treating α­syn with hops resulted in a concentration dependent decrease in fluorescence compared 
with α­syn alone.  The increase in fluorescence of α­syn in the presence of ThT is widely regarded as 
representing an increase in α­syn aggregation (Anderson and Webb, 2011; Giehm et al., 2011; Zhao 
et al., 2011; Ahmad and Lapidus, 2012).  A decrease in fluorescence is likely to be either due to a 
reduction in aggregation, the prevention of the dye binding to the aggregated protein or the loss of 
the protein.  As described in section 4.1, any decrease in fluorescence is most likely due to a 
decrease in aggregation similar to the changes shown in other studies looking at the effects of heat 
shock protein or immunoglobulin on aggregation using a ThT assay (Smith et al., 2012; Daturpalli et 
al., 2013).  There is therefore a concentration dependant inhibition of aggregation observed when 
treating monomeric human α­syn with hops.
56
Hops decreased fluorescence with every increase in concentration.  By including 0.0125% 
w/v of hops prepared at room temperature with 1 mg/mL of α­syn, the maximum fluorescence 
dropped by more than half.  The shape of the curve remained the same, but the intensity was 
reduced, and the lag phase was longer.  Increasing the concentration of hops to 0.025% w/v reduced 
the maximum fluorescence and delayed the lag phase compared to α­syn only.  Finally, a 
concentration of 0.1% w/v hops caused a 53­fold reduction in maximum fluorescence with no 
calculable lag phase.  Compared to heat shock protein (Hsp90), a protein involved in the folding, 
stabilization, activation and assembly of a specific set of proteins, a high enough concentration of 
hops delayed the lag phase similar to how Hsp90 delayed an increase in fluorescence seen in Figure 
4.5 (Daturpalli et al., 2013).
Figure 4.5 The red line represents fluorescence of 70 µM or ~1 mg/mL α­synuclein with 70 µM ThT shaken for 3 days, blue 
represents α­synuclein with C Hsp90 and orange represents α­synuclein with N Hsp90 (Daturpalli et al., 2013).
With a high enough concentration, Hsp90 may lead to a similar reduction in fluorescence. Whether 
hops is only affecting fluorescence and not aggregation was still unclear at this point.  Hops could be
interfering with α­syn aggregates from binding with each other or one of the few possibilities 
discussed previously in the technical considerations.
As mentioned in the technical considerations, ThT is not a viable means to understand the 
effects of a treatment on α­syn aggregation on its own (Hudson et al., 2009).  The hops may not
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affect α­syn aggregation, instead it could be acting on the mechanism of fluorescence.  The hops
may be affecting fluorescence by competitively binding to Thioflavin T, reducing the available 
Thioflavin T that could fluoresce in between the β­sheets.  This could be true because of the dose 
dependent relationship between hops and fluorescence, but still does not eliminate the likelihood of 
hops binding to α­syn.  To determine what hops was binding to, the assay samples were analysed on 
protein acrylamide gels.
4.4 Technical Considerations of gel electrophoresis
Gel electrophoresis was used because it can reveal molecular weights of the proteins present in the 
samples and can also give an approximate representation of protein content in each molecular 
weight.  Gels were silver stained because of the high sensitivity to low protein content, which can 
reveal low concentrations of higher molecular weight oligomers present on the gel compared to 
Coomassie blue staining, which has a lower sensitivity (Oakley et al., 1980). The high sensitivity of 
silver staining was useful in detecting the low protein content of oligomers and other higher 
molecular weight forms of α­syn, but higher content of monomers caused smearing. In future 
studies, it may be worth staining gels with a silver stain to detect oligomers and Coomassie to 
visualise the higher content of monomers.
Additionally, the use of polyacrylamide gels is common place when analysing proteins 
because of the smaller size of proteins 1­200 kDa (Bhilocha et al., 2011).  Agarose gels are usually 
used to analyse DNA with sizes going over 200 kDa.  When analysing aggregated protein compounds 
larger than 200 kDa, using agarose gels to separate fibrillar species may be a viable technique 
(Cowman et al., 2011).
Another limitation to consider with gel electrophoresis in this study was manual pipetting of
small volumes sampled from the ThT assays loaded into the gels. Manual pipetting of a volume as 
little as 10 µL is prone to error (Pandya et al., 2010).  In this study, volumes of 1 µL were taken from 
ThT assay samples to for gel analysis and must be taken into consideration when interpreting results.
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There are strategies that can be used to minimise variability with manual pipetting (Pandya et al., 
2010).
Condensation was also a common occurrence after a week of incubation at 37°C. This may 
explain the increase in protein content in lanes 2 and 3 in Figure 3.14 compared to lanes 1 and 4. In 
the future, microplates should be spun in a centrifuge to recollect any condensation on the seal.
4.5 The effect of Hops on α­syn using gel analysis
A significant difference between protein aggregate sizes was not observed using gel analysis.  The 
presence of putative trimers (42 kDa), quatrimers (~70 kDa) and 10­11 monomers (164 kDa) in 
samples with and without hops showed that hops was not preventing these aggregates from 
forming. A study using a substrate to cause α­syn aggregation observed bands in similar regions (Lee 
et al., 2001). In this study, the sum of total band intensity in each lane was not equal as seen in 
Figure 3.9.  This is likely due to the small volumes pipetted, which may have impacted the amount of 
protein present in each well (Pandya et al., 2010). The lanes containing hops only without α­syn 
showed little smearing and bands that were barely visible, meaning any bands present in the hops 
and α­syn lane were a result of hops affecting α­syn rather than protein extracted directly from 
hops. The presence of higher molecular weight species in lanes containing hops and α­syn show that 
hops is not preventing the formation of aggregates, and when combined with the results of the ThT 
assays where fluorescence was reduced, the hops is likely changing the morphology of α­syn
aggregates. This finding is similar to that of Singh et al., (2013), where curcumin, another 
polyphenolic compound was found to alter aggregate morphology of α­syn rather than preventing 
aggregation altogether. Pandey et al., (2008) also showed a similar effect of curcumin on α­syn 
aggregation and presented gel results similar to this study.  The lanes containing curcumin and α­syn 
still had higher molecular weight species (Pandey et al., 2008) and the atomic force microscopy data 
of curcumin and α­syn resulted in more globular matter than fibrillar outlines (Singh et al., 2013).
Gel analysis confirmed the presence of α­syn and the higher molecular weight species and although
analysis did not conclusively determine the effects of hops on the size of α­syn aggregate species, it 
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did reveal that hops is not preventing aggregation. Hops is most likely changing the morphology of 
α­syn aggregates.
4.6 Effects of temperature on hops treatment
The hops extract was prepared in multiple ways to determine whether different methods of 
preparation may affect any anti­amyloidogenic activity of the extract.  Hops was prepared by 1) 
infusion of homogenised hops in room temperature (22°C) water, 2) 0.2­µm filtration of infused 
hops, 3) by boiling hops for 10 minutes and 4) using a CO2 extract of hops.  The two treatments used 
in this thesis was the room temperature hops preparation and the hops steeped in boiling water.  
The 0.2­μm filtered preparation and the CO2 hops extract both presented technical challenges which 
were not overcome in the time constraints of the present study.
Filtration was initially an issue because the hops particles blocked the filter pores during 
filtration.  Multistep filtration is a solution to this issue but due to time constraints not enough data 
could be collected using filtered hops.
The CO2 extract became cloudy in the ThT samples with and without protein, resulting in 
greater absorbance rather than fluorescence.  There might be other methods to perform another 
colorimetric assay by changing pH and using different dyes (Giasson et al., 2014), however this was 
not pursued as one of the goals of this study is to reduce procedures to maintain efficiency and 
reproducibility.
The only difference between boiling hops and preparing it at room temperature was that 
boiling the hops during preparation resulted in noticeably lower variability between replicates 
making the distinction between treatment concentrations clearer. This tells us two things, firstly the 
active component of the hops homogenate that gives rise to the reduced fluorescence is not 
affected by boiling.  Secondly, while the precise mechanism is of course unknown, perhaps boiling 
results in the addition or removal of some component of the raw homogenate which resulted in the
reduced variability in the fluorescence readings observed when the preparation is boiled.
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Other techniques such as shaking powdered hops with methanol for several hours and 
filtering the supernatant could be used to isolate different constituents in future ThT assays.  This 
technique was used to prepare mulberry leaf extract for a ThT assay that measured the of the 
mulberry leaf on amyloid b­peptide aggregation (Niidome et al., 2007).
The gel analysis showed bands in four molecular weight regions similar to the hops prepared 
at room temperature.  The boiled hops also did not affect the number of aggregate species.  In 
future experiments, treatments that inhibit fluorescence in ThT assays could be analysed further by 
observing effects on fibrils using total internal reflection fluorescence microscopy (TIRFM) as shown 
in Figure 4.1 (Wördehoff et al., 2015).  Any inhibition of α­syn fibril growth would make a treatment 
a contender for behavioural/clinical experiments.
A procedure that could potentially be used before or after ThT assays is a newly developed 
piece of equipment called BLItz that measures binding affinity.  Alpha­syn could be biotinylated and 
then checked for direct binding of a treatment to α­syn using the label free BLItz.  BLItz works by 
using a proprietary sensor that can detect optical changes when proteins bind to the sensor (King et 
al.).  Any further binding to the protein can also be detected by further reduction of light reaching 
the sensor. Using BLItz to measure binding affinity to α­syn should be used as a preliminary 
experiment to behavioural experiments, if the procedure is reproducible and allows a high 
throughput of treatments to be tested.
After the completion of this study, a machine for carrying out dynamic light scattering (DLS) 
became available was used by the lab to analyse α­syn aggregate morphology post­ThT assay.  DLS is 
the measure of light intensity with laser exposure and is a non­invasive technique contrast to SDS­
PAGE (Bitan et al., 2001).  DLS can determine the size of small particles and so measure the change 
in particle size over time by direct measurement of the particles themselves rather than relying on 
the binding of a dye to a molecule as in the case of ThT assay used in the present study.   The 
drawback of this technique is that it can only measure the average size of molecules across the 
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whole solution and does not measure each individual particle (Bitan et al., 2001).  However, DLS can 
still be used if an oligomer population is generally uniform.
Atomic force microscopy (AFM) used in the early stages of this project is another non­
invasive technique worth revisiting, which involves light reflecting off a cantilever that makes 
contact with the surface being measured (McAllister et al., 2005).  We had difficulty using AFM 
initially since we relied on purchasing commercially produced α­syn and could not get it in sufficient 
quantity to use this method.  Since we now make α­syn our selves this technique would be possible 
and would be worth using in future studies.  AFM can visualise individual molecules and so is useful 
in particular for not only reporting the size of the molecules but also showing the morphologies 
assumed by the molecules upon aggregation (McAllister et al., 2005).
Refinements to techniques using SDS­PAGE, may also be useful including chemically 
crosslinking the aggregates to make them more stable prior to running on a gel (Lee et al., 1998; 
Bitan et al., 2001; Bitan and Teplow, 2004).  Some studies used N­ (Ethoxycarbonyl)­2­Ethoxy­l,2­
Dihydroquinoline (EEDQ) to cross­link α­syn before running SDS­PAGE; aggregated α­syn with EEDQ 
resulted in clear high molecular weight bands (Lee et al., 1998).  Samples containing EEDQ could also 
be reanalysed using DLS and/or AFM to check for any possible morphological changes caused by 
EEDQ.
One final method worth noting used to analyse aggregation of α­syn was electrochemical 
analysis.  Lopes et al. (2014) monitored α­syn aggregation by oxidizing tyrosine (Tyr) residues 
surface­exposed in monomeric α­syn and buried in fibrillated α­syn adsorbed onto graphite 
electrodes.  The study performed cyclic voltammetry (CV) and differential pulse voltammetry (DPV) 
and observed increased peaks in voltage when fibrillation occurred, which was further verified by 
the ThT­based assays also conducted (Lopes et al., 2014).  A few of the different techniques could be 
simultaneously completed to provide a more complete picture of the aggregation process occurring 
and verify whether a treatment is disrupting the aggregation process.
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The in vitro portion of this study determined that using a ThT assay as a preliminary test of 
possible PD treatments is viable and that hops was able to dose dependently reduce the 
fluorescence of α­syn compared to un­treated α­syn.  This reduction in α­syn fluorescence was likely 
due to a reduction in α­syn aggregation but as discussed other methods should be performed in the 
future in order to confirm this finding.  With these observations in mind we sought to examine the 
effect of hops treatment on the behavioural effects noted in an animal model of α­syn induced 
behavioural disturbance.  The model used in the present study was C. elegans due to their ease of 
production and rapid turnover.  There was also an α­syn over­expressing strain available which had 
previously reported behavioural deficits.  Since α­syn is increasingly implicated in the initiation and 
or progression of PD, any compound that could modify the pathological behavioural deficits that 
resulted would be of interest for the treatment of human PD.
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5 Results – In Vivo
5.1 Developing in vivo PD model
To establish an in vivo model to test potential therapeutic agents for use against pathologies 
underlying PD, an invertebrate model using C. elegans was chosen. C. elegans were chosen because 
of their short life span and low maintenance requirements, some of the many qualities that make 
them ideal preliminary subjects (Duty and Jenner, 2011). The first method of instigating α­syn 
pathology presented below is the overexpression of α­syn in C. elegans muscle cells.  The second 
method is the overexpression of α­syn in C. elegans food and the final method was the exogenous 
exposure to pre­aggregated α­syn.
5.1.1 The effect of α­syn in C. elegans that overexpressed α­syn
Two strains of C. elegans were used in order to study the effect of α­syn over expression in this 
species.  The DDP1 strain of C. elegans overexpressed α­syn in muscle cells (unc­54 is the gene that 
codes for myosin­4) together with a fluorescent marker (CFP and YFP) (uonEx1 [unc­54::alpha­
syn::CFP + unc­54::alpha­syn::YFP(Venus)]) and the DDP2 strain only has a fluorescent marker 
expressed via the unc­54 promoter fragment ( , serving as a 
control.  The maximum speed, average speed and body bends/second (calculated by dividing the 
Length of the track by Perimeter/2 and the time) of the two strains were compared in these two 
strains. C. elegans were recorded at a single time point 48 hours after being plated, at early stage of 
adulthood. A life span assay was also run alongside the recordings and living worms were tallied 
every second day, however, scoring living worms was unreliable and required more time to 
optimise.
64
Figure 5.1 The mean speeds (pixels travelled/second) of DDP1 C. elegans (overexpress α­syn) (n=108) were compared to 
DDP2 (control) (n=31) with SEM error bars.  (A) shows the comparison of maximum speed.  (B) shows the average speed.  
(C) shows the mean body bends per second.  The nonparametric Mann­Whitney test was used to determine significance. * 
indicates p<0.05.
Both strains were fed OP50­1, a normal strain of E. coli commonly used to feed C. elegans and 
exposed to buffer only (no other α­syn treatments).  Over expression of α­syn in the muscles of C. 
elegans resulted in a significant decrease in both maximum speed (Figure 5.1, panel A) and mean 
bend speed (Figure 5.1, panel C).   The mean maximum speed (A) of DDP2 C. elegans (Mdn=120.60 
px/s) was 1.65­fold greater than DDP1 (Mdn=49.71 px/s), U=1286.64, p=0.011.  The mean bend 
speed (C) of DDP2 C. elegans (Mdn=0.01 bb/s) was 2.1­fold greater than DDP1 (Mdn=0 bb/s), 
U=1345.45, p=0.015).   There was no significant change in mean average speed as a result of over 
expression of α­syn in the skeletal muscles of C. elegans U=1286.64, p=0.25.  It was also noted that 
there was no difference in the length of the worms between each strain.  There was no significant 
difference between mean nematode strain length, U= 1286.64, p=0.16.  
5.1.2 The effect of feeding C. elegans E. coli that overexpress α­syn
The second method of α­syn exposure was feeding normal, wild type C. elegans with a food source 
that over expresses normal human α­syn.  The wild type strain of C. elegans (N2) was used in the 
following experiments.  Control worms were fed OP50­1, a streptomycin resistant strain of E. coli
which is often given to C. elegans.  OP50­1 tends not to form mounds when grown on agar plates 
and so is ideal for feeding c elegans, but is otherwise normal.  The experimental group of C. elegans
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were fed a strain of e coli which over expressed full length, normal human α­syn in order to examine 
the effect of exogenous exposure to α­syn.
Figure 5.2 Three behavioural parameters were compared in the N2 C. elegans fed OP50­1 (control) (n=21) and the 
experimental group that were fed e coli expressing human monomeric α­syn(E­syn) (n=11).  (A) shows the comparison of 
maximum speed.  (B) shows the average speed.  (C) shows the mean body bends per second.  The nonparametric Mann­
Whitney test was used to determine significance. * indicates p<0.05, ** indicates p<0.01.
The C. elegans that fed on E. coli overexpressing α­syn (E­syn) (Mdn=121.93 px/s) showed a 1.75­fold 
increase in maximum speed (A) compared to the elegans that fed on OP50­1 (Mdn=66.18 px/s), 
U=66.10, p=0.0074.  The C. elegans that fed on E­syn (Mdn=48.10 px/s) were 2.14­fold faster in 
average speed (B) compared to the elegans that fed on OP50­1 (Mdn=17.32 px/s), U=66.10, p=0.015.  
There was no significant difference in bend speed (C), however, in C. elegans that fed on E­syn 
(Mdn=0.291 bb/s) compared to the elegans that fed on normal, OP50­1 E. coli (Mdn=0.008 bb/s), 
U=67.78, p=0.11.  There was no significant difference in nematode length between food sources, U= 
66.10, p=0.17.
In summary, wild type, N2 nematodes fed a strain of E. coli that overexpressed α­syn have a 
significantly greater max speed and average speed, but there was no difference in the number of 
body bends per second when compared to C. elegans that were fed non­ α­syn expressing E. coli.
5.1.3 The effect of exposing C. elegans to extrinsic aggregated α­syn
The final method used to induce α­syn pathology in C. elegans in order to examine any potential 
behavioural deficits induced exogenous exposure to aggregated α­syn.  Aggregated α­syn is 
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proposed to be the pathological form of α­syn generating the downstream pathologies associated 
with PD (Danzer et al., 2007; Goedert et al., 2013).  The aggregated α­syn treatment was compared 
to vehicle buffer exposure (same buffer used to dissolve aggregated α­syn).  The wild type N2 strain 
of C. elegans were also used for this experiment.
Figure 5.3 Three behavioural parameters of wild type, N2 C. elegans exposed to 200 µg of aggregated α­syn (n=19) were 
compared with those that were exposed to vehicle only (n=21).  (A) shows the comparison of maximum speed.  (B) shows 
the average speed.  (C) shows the mean body bends per second.  The nonparametric Mann­Whitney test was used to 
determine significance. ** indicates p<0.01.
The mean maximum speed (A) was 2.03­fold greater in N2 C. elegans treated with aggregated α­syn 
(Mdn=146.97 px/s) compared to those treated by vehicle alone (Mdn=66.18 px/s), U=127.13, 
p<0.001.  The mean average speed (B) was 2.32­fold greater in N2 C. elegans in aggregated α­syn 
(Mdn=63.43 px/s) compared to those in vehicle (Mdn=17.32 px/s), U=127.13, p=0.0019.  The mean 
number of bends per second (C) was 3.1­fold greater in N2 C. elegans in aggregated α­syn 
(Mdn=0.329 bb/s) compared to those in vehicle (Mdn=0.008 bb/s), U=128.39, p=0.0051.  There was 
no significant difference in nematode length between treatments, U= 127.13, p=0.19.  The N2 
worms exposed to aggregated α­syn were on average faster over the three parameters examined 
than those exposed to vehicle alone.
5.2 Compounded effects of exposure to α­syn from multiple sources
The two methods of exposing C. elegans used previously were combined to measure the possible 
additive effects of the different methods on C. elegans movement.  Wild type, N2 worms were fed 
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with E­syn and exposed to aggregated α­syn and were compared to those fed with OP50­1 and 
vehicle exposure.
5.2.1 The effects of overexpression of α­syn and exogenous α­syn exposure
The first combination of factors examined in the present study was to use the DDP1 strain of C. 
elegans overexpressing α­syn and combine that with exposure to exogenous aggregated α­syn.
Figure 5.4 Three behavioural parameters were examined between α­syn over expressing DDP1 C. elegans treated with 200 
µg of aggregated α­syn (n=108) were compared to empty vector control c elegans, DDP2, exposed to vehicle alone (n=31).  
(A) maximum speed (B) average speed (C) body bends per second.  The nonparametric Mann­Whitney test was used to 
determine significance. * indicates p<0.05.
There was a significant difference in the mean maximum speed (A) of α­syn expressing c elegans, 
DDP1, treated with aggregated α­syn (Mdn=144.54 px/s) was 1.34­fold greater than vector control 
animals, DDP2 in vehicle alone (Mdn=120.60 px/s), U=1286.64, p=0.02. The mean bend speed (C) of 
DDP1 exposed to aggregated α­syn (Mdn=0.69 bb/s) was also significantly greater than the mean 
bend speed of non α­syn expressing vector control worms, DDP2 in vehicle alone.  The treated 
worms demonstrated a 2.18­fold difference in bend speed compared to the untreated controls 
(Mdn=0.008 bb/s), U=1289.02, p<0.05.  
There was no significant difference in mean average speed (B) of α­syn expressing DDP1 
worms treated with aggregated α­syn (Mdn=52.06 px/s) when compared with non­α­syn expressing 
control animals in vehicle (Mdn=16.72 px/s) by 1.25­fold, U=1286.64, p=0.060.  
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Interestingly, the mean body length of treated animals (DDP1 exposed to aggregated α­syn) 
(Mdn=115.05 px) was longer than the non­treated (DDP2 in vehicle) (Mdn=68.78 px), U= 1286.64, 
p=0.0025 in this experiment.  In summary, the combination of overexpression of α­syn and the 
environmental exposure to α­syn increased movement speed when compared with worms that 
were neither overexpressing α­syn and nor exposed to exogenous aggregated α­syn.
5.2.2 The effects of α ­syn in food and environment
The final combination of factors examined was to expose N2 wildtype C. elegans fed E­syn to 
exogenous aggregated α­syn to see if any effects on mobility were compounded by exposure to α­
syn through multiple administrative methods when compared to untreated wild type worms. The 
combination of exposure to α­syn exogenously while fed E­syn was expected to cause an increased 
reduction in movement speed and bend rate. 
Figure 5.5 Three behavioural parameters were examined in wild type, N2 C. elegans in vehicle fed with normal, OP50­1 
(n=21) bacteria and were compared to the experimental treatment of wild type, N2 c elegans exposed to 200 µg of
aggregated α­syn and fed with E. coli overexpressing a­synuclein (n=23).  (A) maximum speed (B) average speed (C) body 
bends per second were examined.  The nonparametric Mann­Whitney test was used to determine significance. * indicates 
p<0.05, ** indicates p<0.01.
There was no difference in the maximum speed (A) between N2 C. elegans fed with OP50­1 in buffer 
(Mdn=66.18 px/s) compared to those fed E­syn and exposed to aggregated α­syn (Mdn=56.17 px/s), 
U=158.09, p=0.70.  There was also no difference in the mean average speed (B) of N2 C. elegans fed 
with OP50­1 in buffer (Mdn=17.32 px/s) compared to those fed E­syn and in aggregated α­syn 
(Mdn=13.41 px/s), U=158.09, p=0.73; and there was no difference between these treatments in 
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mean bend speed (C), U=164.27, p=0.62.  Lastly, there was no significant difference in nematode 
length between treatments, U= 158.09, p=0.79.  The combined treatment of feeding E­syn and 
aggregated α­syn had no significant effect on C. elegans movement behaviour.
5.3 Anti­amyloidogenic effect of hops in vivo
In the in vitro part of this study, hops reduced fluorescence in the ThT assays which likely 
represented a decrease in α­syn aggregation, suggesting that this hops preparation may be worth 
investigating as a potential therapeutic against the α­syn pathology associated with PD.  In the 
following experiments, the effect of hops extract on the α­syn induced behavioural changes 
observed in C. elegans were examined to see if the hops extract could reverse the observed 
behavioural effect of α­syn exposure.  In addition, the effect of hops on C. elegans behaviour in the 
absence of α­syn was also examined to determine whether any effect of hops was due to interaction 
with α­syn or with the C. elegans alone.
5.3.1 Effects of hops on C. elegans overexpressing α­syn
The following results show the effect of hops on C. elegans overexpressing α­syn (DDP1).  DDP1 was 
expected to reveal any possible effects hops may have on α­syn pathology because of the reduction 
in movement speed compared to DDP2 seen in Figure 5.1.
Figure 5.6 Three behavioural parameters were examined between DDP1 C. elegans (n=108) and DDP1 exposed to hops
(n=39).  (A) maximum speed (B) average speed (C) body bends per second.  The nonparametric Mann­Whitney test was 
used to determine significance. * indicates p<0.05.
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Each of the four parameters examined demonstrated a significant difference compared to the α­syn 
over expressing DDP1 C. elegans alone.  The mean maximum speed (A) of DDP1 exposed to hops 
(Mdn=148.63 px/s) was 2.3­fold faster than DDP1 alone (Mdn=49.71 px/s), U=1659.28, p<0.05.  
Mean average speed (B) of worms exposed to hops (Mdn=55.21 px/s) was 2.5­fold faster than just 
DDP1 (Mdn=14.88 px/s), U=1659.28, p<0.05.  Average number of body bends per second (C) of DDP1 
exposed to hops (Mdn=0.581 bb/s) was 4­fold faster than DDP1 (Mdn=0 bb/s), U=1696.87, p<0.05.  
While the mean length of DDP1 exposed to hops (Mdn=111.78 px) was 2.7­fold longer than the 
DDP1 in buffer (Mdn=34.79 px), U= 1659.28, p<0.05.  Exposure to hops increased worm movement 
speed in the DDP1 strain, but the worms exposed to hops were also longer.
5.3.2 Effects of hops on C. elegans fed E­syn
Even though there was no significant difference in bend between E­syn fed N2 and OP50­1 fed N2, 
the significant difference in movement speed was enough to justify the analysis of hops treatment 
on E­syn.  The effect of hops on movement behaviour of N2 worms fed E­syn was examined next.
Figure 5.7 Three behavioural parameters were examined between N2 C. elegans fed E­syn (n=11) and N2 fed E­syn exposed 
to hops (n=21).  (A) maximum speed (B) average speed (C) body bends per second.  The nonparametric Mann­Whitney test 
was used to determine significance. * indicates p<0.05, ** indicates p<0.01.
There was no significant difference in any of the parameters examined in these experiments when 
worms fed α­syn expressing E. coli were treated with hops extract.  The mean maximum speed (A) of 
worms fed E­syn and exposed to hops (Mdn=148.01 px/s) compared to those only fed E­syn 
(Mdn=121.93 px/s), U=66.10, p=0.54.  Mean average speed (B) of N2 exposed to hops (Mdn=53.48 
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px/s) was also no different than those only fed E­syn (Mdn=48.85 px/s), U=66.10, p=0.71.  Mean 
number of body bends per second (C) in N2 exposed to hops (Mdn=0.431 bb/s) was also no different 
than N2 fed E­syn (Mdn=0.29 bb/s), U=66.26, p=0.16.  Lastly, there was also no significant difference 
in nematode length between treatments, U= 66.10, p=0.68. 
In summary, there was no significant difference in speed between N2 fed with α­syn 
expressing E. coli, E­syn and exposed to hops and those that were not.  It was also noted that the 
variability in the measures taken were greater the worms that were fed E­syn only.
5.3.3 Effects of hops on C. elegans expose to aggregated α­syn
The addition of hops may reduce the changes evident in N2 exposed to aggregated α­syn in Figure 
5.3 similar to how changes were observed when DDP1 was exposed to hops.  The results of this hops 
treatment are presented next.
Figure 5.8 Three behavioural parameters were examined between N2 C. elegans with 200 µg of aggregated α­syn (n=19)
and N2 in aggregated α­syn exposed to hops (n=25).  (A) maximum speed (B) average speed (C) body bends per second.  
The nonparametric Mann­Whitney test was used to determine significance. * indicates p<0.05, ** indicates p<0.01.
Of the four parameters examined in this experiment each of the three behavioural parameters 
demonstrated a significant change as a result of hops treatment, while there was no effect of hops 
treatment on the length of the worms in these experiments.  The mean maximum speed (A) of N2 C. 
elegans treated with aggregated α­syn (Mdn=146.97 px/s) was 76% greater than those also exposed 
to hops (Mdn=82.00), U=154.78, p=0.0010.  Mean average speed (B) of nematodes exposed to 
aggregated α­syn (Mdn=63.43 px/s) was 80% greater than those also exposed to hops (Mdn=19.39 
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px/s), U=154.78, p=0.0095.  Mean number of body bends per second (C) of worms exposed to 
aggregated α­syn (Mdn=0.33 bb/s) was 4.4­fold greater those also exposed to hops (Mdn=0.039 
bb/s), U=155.62, p=0.0032.  There was no significant difference in nematode length between 
treatments, U= 154.78, p=0.43.  Adding hops to aggregated α­syn reduced movement speed.
5.3.4 The effects of hops on C. elegans without any exposure to α­syn
Lastly, in order to determine whether the hops extract its self was having any effect on the worms 
directly as opposed to any effect the hops may be having on any form of α­syn treatment, the effect 
of hops extract on wild type C. elegans, N2, without any other form of α­syn treatment was 
examined followed by the hops treatment of DDP2.
Figure 5.9 Three behavioural parameters were examined between N2 C. elegans (n=21) and N2 exposed to hops (n=54). (A) 
maximum speed (B) average speed (C) body bends per second.  The nonparametric Mann­Whitney test was used to 
determine significance. * indicates p<0.05, ** indicates p<0.01.
There was no effect of hops on any of the four parameters examined in these experiments in wild 
type C. elegans.  There was no significant change in the mean maximum (A) and average speeds (B) 
in N2 exposed to hops (Mdn=81.61, 21.34 px/s) compared to those that were not (Mdn=66.18, 17.32 
px/s), U=400.90 for both, p=0.17, 0.18.  N2 in hops (Mdn=0.059 bb/s) body bends per second (C) was 
also no different than N2 only (Mdn=0.008 bb/s), U=408.83, p=0.28.  There was no significant 
difference in nematode length between treatments, U= 400.90, p=0.97.  It was also noted that the 
variance in speeds of the N2 samples was high with larger error bars.
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Figure 5.10 Three behavioural parameters were examined between DDP2 C. elegans (n=31) and DDP2 exposed to hops
(n=24).  (A) maximum speed (B) average speed (C) body bends per second.  The nonparametric Mann­Whitney test was 
used to determine significance. * indicates p<0.05, ** indicates p<0.01.
When the vector control C. elegans, DDP2, were treated with hops none of the behavioural 
parameters demonstrated a significant change, but body length of the worms was significantly 
longer as a result of hops treatment.   The mean maximum (A) and average speeds (B) were no 
different between DDP2 exposed to hops (Mdn=133.73, 39.80 px/s) compared to those that were 
not (Mdn=120.60, 16.72 px/s), U=256.51 for both, p=0.54, 0.41.  DDP2 (Mdn=0.147 bb/s) body 
bends per second (C) showed no significant change compared to DDP2 exposed to hops (Mdn=0.008 
bb/s), U=260.81, p=0.63.  The mean length of DDP2 exposed to hops (Mdn=149.42 px) was longer 
than the DDP2 in buffer (Mdn=68.78 px), U= 256.51, p=0.017.  The hops did not influence worm 
movement.
6 Discussion – In Vivo
The in vivo part of this study was completed to investigate a behavioural model of PD pathology by 
1) measuring the effects of aggregated α­syn on C. elegans behaviour and 2) any effects of 
treatments on behaviour altered by α­syn pathology. One of the major considerations of this study 
was whether C. elegans may be useful as an in vivo model to examine pathological mechanisms 
proposed to underlie human PD.  Thus, this possibility will be discussed next followed by an 
examination of the behavioural results obtained.
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6.1 C. elegans as a model for PD
There are a number of animal models of PD which have been used to examine PD experimentally 
over the two hundred years since the first description of the disease in 1817 (Duty and Jenner, 2011; 
Blesa and Przedborski, 2014).  Some major models include: 6­OHDA mouse and rat primate, MPTP 
mouse & primate, rotenone and paraquat mouse and rat – all of these only serve to examine the 
effect of dopamine cell loss as they specifically kill dopaminergic neurons via their specific 
mechanisms but do not induce other principle pathologies underlying PD (Blesa and Przedborski, 
2014).  Higher order animals such as rodents and primates are expensive and require a great deal of 
special care and a reasonably large amount of space for housing.
For financial and ethical reasons, the numbers of animals available for experimentation with 
these models is often quite limited and so complex experiments requiring large numbers of groups 
may not be possible, or mechanisms resulting in little change requiring the greater statistical power 
offered by larger numbers are not always available particularly for primate models.  In addition, the 
death of dopaminergic neurons is but one characteristic of PD and one that does not occur for some 
years following the initiation of the disease, so particularly for studies that aim to examine the 
initiation of PD, rather than simply the cause of the motor deficits associated with the disease, 
models which examine other primary pathologies associated particularly with the earliest stages of 
the disease may be more useful.  Genetic models are useful as they examine specific genetic deficits 
which have been associated with familial forms of Parkinsonism in humans, however since these 
forms of Parkinsonism represent only 5­10% of Parkinsonian cases the development of other models 
not necessarily examining the specific genetic deficits directly may be useful.
One of the other characteristic pathologies of PD, and one which appears to occur at the 
earliest stages of the disease (Dehay et al., 2015) is the formation of intra cellular protein aggregates 
referred to as Lewy bodies (LB).  This LB formation and the proteins involved appear to be one of the 
important steps in the initiation of PD, but little research has been done into this earliest of 
mechanism.  It has been noted that one of the most prevalent proteins involved in the formation of 
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LB is the pre­synaptic protein α­syn.  Support for the importance of α­syn in the initiation or 
progression of PD lies in the observation that several mutations to the α­syn gene, SNCA result in 
several of the familial forms of Parkinsonism referred to above.  Again, while these specific genetic 
deficits have not been associated with sporadic PD which constitutes greater than 90% of cases, the 
triggering of parkinsonism as a result of damage to the α­syn protein is taken as evidence that α­syn 
may play an important role even in the sporadic form in which there is no known genetic deficit.
Thus, an animal model in which α­syn is used to initiate some form of measurable disease
pathology would be useful for the study of the initiation or progression of the human disease, as 
these processes seem to be highly implicated in the earliest stages of the disease.  Mouse models 
have been developed in which α­syn is either over expressed or injected into selected parts of the 
brain (George et al., 2008), but as described above particularly for early stage investigations or the 
screening of large libraries of potential therapeutic compounds rodent models may be difficult or 
expensive to use, requiring resources or facilities not widely available.  An invertebrate model may 
be useful in that pathological mechanisms may be investigated in a living organism without the same 
ethical constraints that can hinder experiments using higher order animals including vertebrates.  C. 
elegans have been used to model many human diseases, they require little space and due to their 
ease of breeding can be expanded into numbers which provide more meaningful results for these 
sorts of experiments.
C. elegans were considered a viable model because of their unique characteristics. For this 
investigation, there were many reasons to prefer C. elegans over other organisms.  C. elegans are 
about a millimetre long when fully grown and do not require a dedicated facility to maintain.  The 
small size enables many nematodes to be maintained on a petri dish filled with agar (Dexter et al., 
2012).  Other invertebrates have been used to study PD such as drosophila melanogaster
(Whitworth et al., 2006).  However, behavioural analysis of drosophila can be difficult due to rapid 
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movements in three dimensions of this species, C. elegans on the other hand stay on a 2­
dimensional surface agar plate (Dexter et al., 2012).
C. elegans were also chosen because of their short life span.  Their lifespan depends on the 
temperature around them and they can live up to 20 days (Bodhicharla et al., 2012).  Having a short 
life span means more experiments can be run in a shorter period and more treatments can be 
tested, allowing for high throughput screening of compounds or treatments of interest.
One of the goals of this study was to establish a preliminary animal model of PD pathology
using C. elegans. According to the currently understood mechanism of cellular death in PD, 
oligomers were shown to be cytotoxic in vitro when they were taken up by neurons (Cremades et 
al., 2017).  The fundamental elements to establish a model of PD pathology are neurons that are 
susceptible to cytotoxic species of α­syn.
The C. elegans used, however, overexpressed α­syn in muscle cells not in the neurons.  
Although overexpression was in the muscle cells, C. elegans had reduced lifespans.  C. elegans
overexpressing α­syn also showed reduced motility and pharyngeal pumping compared to N2 wild 
type C.  elegans (Bodhicharla et al., 2012).  In humans, PD not only causes motor control issues and 
tremors, but also cause oesophageal and pharyngeal dysfunction (Johnston et al., 1995). Reduced 
pharyngeal pumping observed in worms is reminiscent of human difficulty swallowing.  In addition, 
human lifespan of individuals with PD is also reduced (Hobson et al., 2010; Apfeld and Fontana, 
2017).
Bodhicharla et al., 2012 also showed localisation of α­syn in neurons in the strain 
overexpressing α­syn in muscle cells. Although the cellular complexity is not the same, this
represents a likeness to the presence of α­syn deposits in the substantia nigra in human PD (Baba et 
al., 1998). Taken together the α­syn over­expressing strain of C. elegans used in this study 
demonstrate several characteristics which are similar to the human condition, potentially making it a 
useful model in an experimental setting.
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6.2 PD pathology in C. elegans
The first goal of the in vivo part of this study was to induce α­syn PD pathology in C. elegans using 
different methods of administration and exposure to α­syn. 1) Alpha­syn production was 
overexpressed in a C. elegans strain, 2) C. elegans were also fed a strain of E. coli that overexpresses 
α­syn and 3) C. elegans were exposed to aggregated α­syn (oral administration). The effects of each 
method would be compared using movement speed, bend speed and worm size.
6.2.1 Overexpression of α­syn in C. elegans as a model of PD pathology
C. elegans overexpressing α­syn (DDP1 strain) were analysed in this study because they showed
reduced pharyngeal pumping and shorter life spans in a previous study (Bodhicharla et al., 2012).  
This is comparable to dysphagia, the cardinal motor deficit of bradykinesia and the reduced lifespan 
seen in humans with PD (Mu et al., 2012).  DDP1 overexpresses α­syn in muscle cells (unc­54 gene)
with a fluorescent marker.  DDP2 only expresses the fluorescent markers via the promoter fragment 
of the unc­54 gene.  DDP1 worms were expected to be slower than their control counterpart DDP2
because of the other effects of α­syn observed on lifespan and pharyngeal pumping.
When treated with buffer and fed normal E. coli, OP50­1, the maximum and average speeds 
of DDP1 were less than DDP2.  The difference between DDP2 and DDP1 was more than 1.5­fold in 
maximum speed and bend speed (p<0.05).  There was no difference in body bends per second 
between DDP1 and DDP2 (p=0.26).  Overexpression of α­syn was expected to have a direct effect on 
mobility with no evidence of reduced movement speed in prior research.  Based on the behavioural 
results described here, the over expression of α­syn in muscle cells of the DDP1 strain of C. elegans
does result in a significant reduction in average speed.
Comparing the results of this study to previous findings, a study examining DDP1 reported
the effects of α­syn overexpression on egg to adult development time, brood size, life span,
pharyngeal pumping and locomotion (bend) rate (Bodhicharla et al., 2012).  Egg to adult 
development and brood size were the same between transgenic strains and N2. C. elegans
overexpressing α­syn also had shorter life spans, reduced by about 5 days compared to the nearly 
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20­day life span of wild type C. elegans. Pharyngeal pumping and locomotion (bend) rate were
slower in α­syn overexpressing C. elegans compared to wild type N2 (Bodhicharla et al., 2012).
Compared to the findings in this study examining DDP1, the bend rate of DDP1 was also reduced
compared to DDP2. There was also no difference in worm/brood size between the strains in both 
studies.
The overexpression of α­syn in C. elegans muscle cells is not commonly found in the 
literature.  The findings of this study, however, can still be compared to other studies also looking at 
C. elegans affected by the expression of A53T mutation of α­syn, who found a reduction in bend 
speed relative to wild type C. elegans (Lakso et al., 2004).  Another study also looking at A53T α­syn
expression showed bend speeds reduced by up to 35% compared to wild type N2 C. elegans
(Kuwahara et al., 2006); while, this study showed a 50% reduction. Although the expression of α­syn
in this study was different to the studies mentioned now, the effect on bend rate is consistent with 
the literature.
A reduced bend rate in DDP1 compared to DDP2 is very likely an indication of α­syn oligomer 
cytotoxicity because the study mentioned above, Lakso et al. (2004), showed neuronal loss in worms 
affected by A53T α­syn expression. Kuwahara et al. (2006) also found worms affected by the A53T 
mutation to have fewer dopaminergic neurons.  The reduced bend rate found in the DDP1 observed 
in this study is likely caused by α­syn pathology.
When considering movement speed that is the velocity of worms moving across the agar, 
greater movement speed does not always indicate healthier behaviour.  The addition of a food 
source for example, according to one study can result in decreased velocity in order to increase 
exposure to food (Kuwahara et al., 2006), and so is not necessarily a measure of loss of function.
The introduction of food in another study was shown to have no effect on worm speed (Angstman et 
al., 2016).  To prevent worm speeds from being affected by food exposure in the present study, 
bacteria were added 2 days prior to recording to both DDP1 and DDP2.  This does not fully discount 
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the possibility that the worms slowed down because they were passing through bacteria, but both 
strains were treated the same way and both strains were expected to slow for feeding, meaning 
changes in speed are likely due to α­syn expression.
While there is currently limited research on the effects of overexpression of α­syn on C. 
elegans movement speeds, the findings in this study can still be compared to those looking at C. 
elegans movement speed affected by amyloid β expression, the protein associated with Alzheimer’s 
(Dosanjh et al., 2010).  Dosanjh et al. (2010) categorised movement speed into two categories: 1) 
enhanced slowing response (ESR), a conserved response to starvation and 2) basal slowing response 
(BSR), an adaptive mechanism that increases the amount of time animals spend in a nutrient rich 
environment.  The study found a reduced ESR in amyloid β expressing worms, although this signifies 
an increase in movement speed, what this result shows is a change in worm speeds under the effect 
of a cytotoxic protein.  The significant reduction in movement speed in DDP1 compared to DDP2 was 
probably caused by α­syn cytotoxicity.
This study can confirm that looking at movement/bend speed of DDP1 to study α­syn
pathology in C. elegans is possible and may even be a preferable method over the use of A53T 
mutation, which better models genetic PD because the A53T mutation is found in familial cases of 
human PD (Goedert et al., 2017), whereas DDP1 might better simulate sporadic PD.  Bodhicharla et 
al. (2012) showed an increase in α­syn aggregation with age.
One recommendation for future analysis of C. elegans in this study is the recording of 
multiple time points to observe any attenuated changes in movement behaviour.  This study did not 
look at the progression of movement changes over a period.  C. elegans were only observed at a 
single time point.  Multiple time recordings would provide further evidence of any effects of α­syn
on C. elegans.  Finally, the results from this investigation support the use of DDP1 C. elegans strain to 
model PD pathology exhibited by changes in movement speeds (Angstman et al., 2016).
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6.2.2 Overexpression of α­syn in C. elegans food as a model of PD pathology
The next method of α­syn exposure examined was feeding the N2 wildtype strain of C. elegans with 
E. coli that overexpresses α­syn (E­syn; the same strain used to produce α­syn).  This method was 
based on evidence that different E. coli can influence C. elegans physiology.  One study showed the 
transfer of silver nanoparticles from E. coli to the gut lumen, subcutaneous tissue and gonad of C. 
elegans (Luo et al., 2016).  The silver nanoparticles reduced reproduction and life span in affected 
worms. The results of E­syn ingestion are presented next.
The N2 worms fed E­syn demonstrated a significant increase in maximum speed, and 
average speed and though there was a trend towards an increase in the number of body bends per 
second, this did not reach significance (See Figure 5.2). The change in maximum and average speed 
was between 1.75 and 2­fold. There was also no difference in length of worms as a result of each 
treatment.
There are no previous studies looking at the effects of C. elegans’ ingestion of E. coli
overexpressing α­syn, the results in this study were instead compared to studies looking at the 
effects of movement behaviours of C. elegans being fed E. coli stimulated to express OxyS, a 
noncoding RNA that protects the bacterial cells from oxidative damage.  A study found that the OxyS
changed foraging behaviour in N2 wild type worms causing them to move away from OxyS 
expressing bacteria (Liu et al., 2012). In this study, the wild type worms exposed to E­syn could also 
be moving away from the E­syn and foraging for non­α­syn­expressing E. coli, which may explain the 
increased movement speed.
The lack of any change in body bends/second may be because the form of the protein in E­
syn is mostly monomeric as seen in the early stages of Figure 3.1.  The protein produced by the E. 
coli is still monomeric, which has not been shown to be neuro toxic.  It has been shown that 
oligomeric species are the pathological forms of α­syn, demonstrating both increased levels of 
cytotoxicity and increasing levels of aggregation (Danzer et al., 2007). The insignificant difference 
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between bend rates might also be because the amount of α­syn in the E­syn present on each plate 
was too low to have an effect.
If the content of α­syn was too low to have any significant effect on younger worms, another 
time point is recommended for future studies. As Bodhicharla et al. (2012) showed an increase in 
effects on pharyngeal pumping and bend rate as worms aged, an indication of progressive changes 
that could be detected in a second recording.
The increased movement speed was unexpected, but is likely because the N2 worms eating 
E­syn had more food available.  The OP50 strain of E. coli is specifically used due to its limited growth 
on NGM plates because it is unable to synthesize uracil (Hahm et al., 2011; Porta­de­la­Riva et al., 
2012).  E­syn is only modified to overexpress α­syn and not to limit growth on NGM, meaning the 
rate of bacterial growth for the E­syn group would be larger and therefore results in more food 
availability on the plate after 48 hours of incubation. The increased movement speed was not 
caused by an increase in worm size because there was no difference between N2 with normal food 
and E­syn. The N2 worms with E­syn might be faster because of the prior exposure to increased 
food content (Angstman et al., 2016).
One way to avoid increased E­syn in future experiments would be to perhaps, use an OP50 
strain modified to overexpress α­syn so that the growth rate of the food given in both experiments is 
equivalent.  Another way to ensure worms exposed to E­syn do not have more food in the period of 
observation is to kill the bacteria before storage.  In this study, the bacteria were stored live at 4°C 
after the final concentration was prepared.  In the future, all E. coli used to feed the C. elegans could
be heated to 70°C for 2 minutes to kill bacteria before feeding thus eliminating the growth rate of 
the food source as being a variable in these experiments (Stringer et al., 2000). Heating may have a 
two­fold effect useful for this study, the first would be to kill the bacteria and the second to possibly
cause the α­syn to aggregate (Ferreon and Deniz, 2007), which might increase the presence of 
oligomers.
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Another possible explanation for the reduced bend rate and increased movement speed in 
using E­syn was that the strain of E. coli used may be more nutritious than OP50.  Xu et al., (2017) 
showed that feeding E. coli expressing a polypeptide found in scorpion venom increased lifespan and 
reproduction.  This may be the case with the E­syn used in this study, where E­syn expressing 
monomeric α­syn, a protein that does not exhibit α­syn toxicity, but rather may exhibit increased 
levels of nutrition.  The results of this study, nonetheless, show that feeding C. elegans E­syn may 
have affected movement speeds, but the changes in movement speed may not be due to α­syn 
toxicity because the cause of the effect is not entirely clear with less literature on behavioural effects 
of E. coli expressing α­syn.
Analysing C. elegans fed E­syn using an immunohistochemistry assay in addition to 
behavioural analysis would add evidence to a possible effect of α­syn (Lakso et al., 2004; Kuwahara 
et al., 2006).  Methods on antibody staining in C. elegans can be found in the literature using “freeze 
cracking” (Crittenden and Kimble, 1999; Duerr, 2013).  This method is used because of the inability 
to take slices as is usually done with larger tissue samples.  Freeze cracking is the freezing of C. 
elegans between to slides and then splitting the frozen slides, resulting in a percentage of worms 
being split onto each slide allowing staining to reach the interior parts of the worm (Crittenden and 
Kimble, 1999). Several different monoclonal antibodies can be used to detect human α­syn.  Some 
of which include mouse monoclonal antibodies LB509, SYN211, or a rabbit poly­ clonal antibody 
number 259 (Kuwahara et al., 2006).  Any increase in fluorescence in stained worms affected by E­
syn would substantiate any behavioural changes observed in the in vivo assays performed in this 
study.
6.2.3 Effects of exogenous exposure to aggregated α­syn on C. elegans
The final means of treating C. elegans with α­syn was the external administration of pre­aggregated
α­syn.  This method relies on the way that C. elegans feed.  C. elegans feed via rhythmic contractions 
and relaxations of their pharynx (Trojanowski et al., 2016). By mixing aggregated α­syn with OP50­1, 
the worms were expected to incidentally ingest the aggregated form of the protein during normal 
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foraging behaviour and should not be able to filter out the aggregates (Fang­Yen et al., 2009). The 
expected result was that there would be a difference between vehicle treated and the α­syn treated 
animals.  Since α­syn and in particular aggregated α­syn has been associated with increased levels of 
cell death and increased levels of mitochondrial dysfunction, it was expected that there would be 
reduced mobility in worms exposed to aggregated α­syn (Li et al., 2007; Cole et al., 2008).
The worms exposed to aggregated α­syn, however, showed greater movement and bend 
speeds than worms exposed to buffer and no difference in worm size between treatments (p<0.05).  
This result was similar to the worms treated with E. coli which expressed monomeric α­syn.  In both 
cases the oral intake of either monomeric α­syn or aggregated α­syn both resulted in an increase in 
mobility in this species.  The reason for this is unknown but will be examined here.
Exposing C. elegans to exogenous aggregated α­syn is a novel part of this investigation.  C. 
elegans overexpressing α­syn are usually used to model PD because of evidence of neuronal loss in 
transgenic C. elegans (van Ham et al., 2008).  Hence, the results cannot be directly compared to the 
literature, but the results can be compared to a study observing delivering proteins using lipid 
vesicles (Perni et al., 2017).  The study incubated an antibody that inhibits α­syn aggregation with 
lipid vesicles to encapsulate the antibodies and then incubated transgenic C. elegans expressing α­
syn with encapsulated proteins.  Perni et al. (2017) first showed that the antibody was indeed taken 
into the worm bodies and then analysed using different fitness parameters such as body 
bends/minute, speed, bend amplitude, displacement per bend, and moving fraction. The study 
showed an increase in movement parameters when treated with antibodies.
In this study, α­syn may be affecting the C. elegans because no other factors were different 
between the two subjects.  A recommendation for future experiments is to incubate α­syn 
aggregates in lipids to encapsulate the α­syn and make them more readily absorbable by the C. 
elegans (Perni et al., 2017) along with immunostaining and confocal examination to carefully 
monitor the uptake of α­syn. A fusion protein of α­syn and Venus, a fluorescent protein that can be 
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used to tag proteins, could be aggregated and administered to the C. elegans (Levin et al., 2016).
Venus is a version of yellow fluorescent protein (YFP) and more acid tolerant than YFP (Emission at 
530 nm with excitation at 515 nm) (Nagai et al., 1989). Fluorescence in C. elegans would indicate 
the presence of aggregated α­syn, but not monomers (Levin et al., 2016), however, this could be 
advantageous when observing the cytotoxic effects of α­syn aggregates.
6.3 The combined effects of α­syn exposure using multiple methods
In this experiment, exogenous exposure to aggregated α­syn was combined with one of the first two 
methods of exposure to α­syn (1) DDP1 and 2) N2 worms fed E­syn) to see if any effects would be 
amplified. Aggregated α­syn was expected to seed further aggregation of α­syn as shown in 
previous research and to increase any cytotoxic effects (Danzer et al., 2007; Kim et al., 2007; Ono et 
al., 2012).  The results of the combined treatments were analysed next.
6.3.1 The effects of overexpression of α­syn and exogenous α­syn exposure
DDP1 exposed to aggregated α­syn showed greater maximum speed and body bends/second than 
DDP2 exposed to buffer (p<0.05), but DDP1 worms were 70% longer than DDP2 (p<0.05). A 
difference in worm size is usually indicative of an unsuccessful synchronisation (Bodhicharla et al., 
2012; Chew et al., 2013).  Since all DDP1 worms were synchronised together and no other 
treatments showed a significant difference in worm lengths, the cause of the difference in length 
may be another factor (Nagashima et al., 2017).
Nagashima et al. (2016) showed dopamine negatively regulates C. elegans body size by 
binding to a dopamine receptor that is similar between species.  The study confirmed that the 
change in body size was not due to faster development and the C. elegans with increased dopamine 
levels were in fact smaller than those with reduced dopamine levels by (Nagashima et al., 2016).
The findings of Nagashima et al. (2016) provide a few clues and possible recommendations for future 
experimental attempts.
Firstly, an increase in body size in DDP1 in this study could mean that there may be a 
reduction in dopamine levels. Secondly, unlike the Nagashima et al. (2016) study, this study did not 
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monitor other developmental stages of the worms to check if some worms developed faster after 
synchronisation.  It is unclear whether the DDP1 exposed to hops developed more quickly or were in 
fact larger than the DDP2 in vehicle control.  In future studies, a second or third recording after the 
initial recording as suggested earlier would not only provide evidence of increased changes in 
movement behaviour, but also determine whether the worms are still growing. In this study, it is 
possible that the aggregated α­syn seeded aggregation in the DDP1 already overexpressing α­syn 
(Danzer et al., 2007), which may have reduced dopamine levels via cytotoxicity in neurons.
Even though there was an increase in maximum movement and bend speed of DDP1 with 
aggregated α­syn compared to DDP2 in vehicle, there was no significant difference between average 
speeds and the increase in size was not proportional to the increase in maximum speed and bend 
speed. This result might be caused by the increase in worm length, but is difficult to comment on 
these findings without further confocal examination of these worms.
6.3.2 The effects of α ­syn in food and environment
When the N2 were exposed to both E­syn and α­syn, there was no significant difference when 
compared to the N2 exposed to only α­syn (p>0.05), in other words the combined exposure of α­syn 
from the food and the aggregated α­syn had no additive effect.  According to prior analysis, both 
monomeric α­syn (from the E­syn) and aggregated α­syn applied exogenously enhanced worm 
movement speed therefore an additive effect was expected when exposed to both E­syn and α­syn.
However, this did not occur, suggesting that the observed increase in locomotion occurred by the 
same mechanism regardless of the form of α­syn delivered. This finding may not be consistent with 
the literature.
Chen et al. (2016) conducted an experiment like the experiment here in section 6.3.2.  Their 
study examined the effects of an E. coli strain that produces the extracellular amyloid protein curli 
on an α­syn expressing C. elegans strain (Chen et al., 2016).  The study found an increase in α­syn
aggregates in the head region and as the worms aged, an increase in α­syn deposits in the tail.  The 
study also saw a 15­20% reduction in thrashing (similar to body bends/second).  This experiment 
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looking at the effects of E­syn and α­syn exposure did not find any changes in body bends/second, 
but the results from the experiments looking at the effects of E­syn also pointed to the possibility of 
E­syn not being toxic to C. elegans.
6.4 Treating PD pathology in C. elegans
Hops was used to treat C. elegans with one of the 3 methods of α­syn exposure/overexpression.  The 
results of each are discussed below. This is followed by a discussion on the effects of hops on C. 
elegans without exposure/overexpression of α­syn to see the general effect of hops on worms.
6.4.1 Hops treating DDP1
According to the inhibitory effect of hops on α­syn aggregation observed in the ThT assays, hops 
could potentially affect any α­syn cytotoxicity found in one of the exposure methods used.  DDP1 
originally had reduced maximum speeds and bend speeds when compared to DDP2.  When DDP1 C. 
elegans were exposed to hops, the worms showed a significant increase in mobility.  DDP1 exposed 
to hops were over two times faster than just DDP1 (p<0.05).  However, the DDP1 strain exposed to 
hops were also more than double the length of the untreated DDP1 strain which may have caused 
the observed increase in speed equivalent to the increase in size.  It is possible that the hops may 
have increased the size of the worms but further investigation is needed to confirm this.
Treating C. elegans with hops is another novel part of this study, the findings of treating 
DDP1 with hops were compared to a study looking at the effects of betulin (an active compound 
found in the bark of birch trees) in transgenic C. elegans expressing α­syn.  The study tested different 
concentrations of betulin to determine the optimal concentration to use to study the any 
neuroprotective effects of betulin (Tsai et al., 2017).  The study found that increased concentrations 
of betulin caused a reduction in body sizes.  Tsai et al. (2017) also went on to find increases in life 
span and food sensing behaviour (the reduction in bend speed near a food source) in worms when 
treated with betulin.  Considering the effect of betulin on worm size, the concentration of hops used 
may have increased worm size.  The increase in size may also be the cause of the proportional
increase in movement/bend speed.
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Due to the limited literature on the treatment of C. elegans affected by α­syn with hops, 
which contains polyphenols, the findings of this study were also compared to studies treating C. 
elegans affected by amyloid beta with polyphenols such as quercetin (Jagota and Rajadas, 2012; 
Regitz et al., 2014). One study found that the quercetin reduced paralysis in worms affected by 
amyloid beta (Regitz et al., 2014).  Another study found that ferulic acid showed greater protection 
against amyloid toxicity than polyphenols: morin, quercetin, and gossypol (Jagota and Rajadas, 
2012). These findings show the potential effect of different polyphenols on the physical phenotype 
of movement and the level of efficacy of each.
Since the hops treated DDP1 were larger than the untreated DDP1, the changes in 
movement/bend speed are difficult to assess.  Nonetheless, this studied showed that hops did affect 
worm growth and increased the reduced speeds observed in untreated DDP1. The speed effects of 
hops on DDP1 most likely involved α­syn because hops treatment of DDP2 in section 6.4.4 resulted
in DDP2 increased body growth, but no significant change in speeds. Recording worms at a second 
time point to measure any changes in worm growth of the untreated DDP1 would help determine if 
the hops affected development rate or final body size. Observing all the C. elegans at another time 
point may also reveal in progressive decline in mobility due to longer exposure to α­syn, perhaps 
recording again 1­2 weeks after the first recording. The effects on aged worm populations is another 
advantage of recording at another time point because van Ham et al., (2008) showed aged C. 
elegans contained aggregated α­syn. This study did not attempt secondary recordings due to time 
constraints. In future experimentation, testing saturated concentrations of hops to evaluate optimal 
concentrations to use on worms is also recommended.
6.4.2 Hops treating E­syn fed C. elegans
Feeding N2 with E­syn resulted in increased maximum and average speeds.  E­syn fed C. elegans
with hops did not result in any significant change between speeds or worm length. Considering the 
possibility that E­syn did not negatively influence the movement behaviour of N2 wildtype worms 
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with no significant difference in bend speeds, it is possible that there was no α­syn toxicity for hops 
to inhibit.
Even though treatments are found to increase life span or enhance worm movement 
(Cañuelo et al., 2012), some studies seem to suggest a targeted mechanism of action, where the 
treatment may be inhibiting aggregation and toxic species (Jagota and Rajadas, 2012).  In this 
experiment, the hops may not have an effect on exposure to E­syn because of the lack of toxic 
protein aggregates.  The experiments observing the effects of hops on C. elegans untreated with α­
syn in section 6.4.4 present more evidence to this possibility.
6.4.3 Hops treating aggregated α­syn exposure
N2 exposed to aggregated α­syn treated with hops, on the other hand, showed decreased
movement speeds compared to N2 with α­syn.  Hops binding to α­syn and preventing any enhancing 
effect on worm movement speed is a possible explanation, but further evidence is required.  There 
was no significant difference in length between N2 exposed to aggregated α­syn.
The results of this experiment seem to indicate that hops is reversing the increased 
movement and bend speeds caused by the exogenous exposure to aggregated α­syn.  Although the 
α­syn caused increased speeds and hops reduced these speeds, the increased movement speeds 
maybe a phenotype indicative of an effect of α­syn.  This is similar to how worms are unable to slow 
down to forage for food when exposed to 6­OHDA and then when treated with betulin, were able to 
slow their bending frequency near food (Tsai et al., 2017). The experiment discussed next helped 
determine if hops was generally enhancing worms or if hops was targeting α­syn.
6.4.4 Effect of hops on C. elegans without α­syn exposure
Hops exposure was compared in DDP2 and wild type N2.  When DDP2 were exposed to hops, there 
was no significant difference in movement speeds.  The same was true of the N2 exposed to hops
and fed OP50­1 meaning that hops did not affect movement speeds. There was no change in N2 
body size when treated with hops, but there was a significant increase in body size of DDP2 treated 
with hops.  Since the DDP2 showed an increase in body size, but no difference in speeds, the effect 
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of hops on DDP1 speeds was more likely due to an interaction of hops with the overexpression of α­
syn.
Summarising the effects of hops, this study found that hops reversed any possible effects 
caused by α­syn exposure in DDP1 and N2 exposed to aggregated α­syn, and did not affect DDP2 or 
N2 without α­syn exposure.  This study presents evidence that hops may be affecting α­syn toxicity 
produced in C. elegans.
There is limited research on the effect of hops on C. elegans, but considering the safety of 
hops in humans, hops is safe for consumption (Sasaoka et al., 2014).  The potential effects of hops 
on α­syn exposure should be validated using immunostaining and confocal microscopy before 
moving onto clinical trials as this study provides evidence of the potential effects of hops on worm 
behaviour.  The final experiment discussed is a high throughput life span assay.
6.5 High throughput life span assay
A high throughput life span assay was attempted using previous methodologies, but this study found 
data collection to be unreliable.  Using a 96 well plate and magnification strong enough to count 
living worms is not feasible in large numbers when depending on human eyes; tracking moving 
worms leads to double counting and miscounting. Worms did not always move even after a stimulus 
of light (from the microscope) and gentle tapping on the plate. These worms were counted as dead
because animals that did not move and were determined dead in the preceding count might move 
later on. Solis and Petrascheck (2011) suggested the use of strong light, specifically blue light to 
induce movement and to shake the 96­well plate on a microtiter plate shaker for 2 min before 
counting. A recurring issue was that worms sometimes swarmed together, making the life and 
death count less reliable because the dead worms appeared to move when adjacent living worms 
moved.
This life span assay was repeated 4 times and the same issue of observing worm count came 
up every single time.  The size of the well and the field of view of the microscope are very important 
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to the success of counting living worms.  Taking small video snippets of the field of view and using 
video analysis is the ideal method of counting living worms whilst minimising potential human error.
Analysing worm movement behaviour was found to be more time efficient compared to 
measuring life span and may detect more minute changes in treatment effects (Angstman et al., 
2016).
6.6 Recommendations for developing a PD model in C. elegans
Some recommendations for future optimisations were already mentioned such as secondary 
recordings, confocal analysis of worms and testing saturated concentrations of treatments before 
analysing the effects on α­syn exposure.  More recommendations are discussed below.
Another limitation considered was the use of 5.5 cm plates.  This plate was larger than the 
field of view that the microscope used.  Multiple fields of view were filmed on a single plate and 
while the fields were distant from each other and did not overlap, it remains possible that fast 
worms could have moved to other fields of view and therefore been double counted.   The use of a 
different microscope allowing a larger field of view, or only measuring one field of view per plate 
would prevent this from happening in future experiments.
Treated worms could be observed in 12­well plates instead of 5.5 cm plates.  This would 
eliminate the need to record worm plates in quadrants and reduce the likelihood of multiple 
recordings of the same worms.  This would also reduce the amount of space necessary to store 
numerous treatments and more treatments could be tested in less time.
One final optimisation would be to double blind researchers to the treatments used from 
recording to analysis.  This would reduce any bias to any treatments that pass each stage of testing, 
making them likely to be candidates for PD therapy.
6.7 Conclusions
This study considered the issue of current PD treatments that current treatments do not target 
disease progression.  The aims of this study were to develop an in vitro and an in vivo assay targeting 
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the earliest pathology known in PD.  The target was the aggregation of α­syn.  In the in vitro assay, 
ThT, a dye widely used in research to measure aggregation rate, was used to measure α­syn 
aggregation and then to test a potential PD treatment, hops.  In the in vivo assay, transgenic and 
wild type C. elegans were exposed to α­syn or hops and movement/bend speeds were analysed.
The aim to develop an in vitro assay that can measure the effects α­syn aggregation and to 
test a treatment was considered successful because the study found the use of ThT to be consistent 
with the literature where the fluorescence curves were similar to prior research. The fluorescence 
curves using 1 mg/mL of α­syn showed similar maximal fluorescence, peak rate and lag phases when 
compared to similar methodologies. Using the ThT assay to measure the effects of a particular 
treatment on α­syn aggregation showed a dose relationship between hops treatment and maximal 
fluorescence, peak rate and the lag phase.  Hops did not show any change in higher molecular 
weight species of α­syn using gel analysis. The effect of hops on the aggregation of α­syn suggested 
that hops may potentially affect aggregation in vivo.  The use of electron microscopy to analyse the 
development of aggregation when treated with hops is recommended to further validate these 
findings, but these findings were also confirmed using the in vivo assay.
C. elegans were used in this study because of their low maintenance, cost and high 
reproduction rate.  The study found significant behavioural changes in line with prior research in 
transgenic C. elegans expressing α­syn.  DDP1, the α­syn expressing strain, had reduced maximum 
movement speeds and body bends/second.  The exposure of E­syn and aggregated α­syn, however, 
had an inverse effect, increasing N2 wildtype worm movement and bend speeds.  Nonetheless, the 
α­syn exposures affected the C. elegans behaviour and as observed in the literature, increased 
speeds can also indicate poor foraging behaviour.  These findings demonstrated the practicality of C. 
elegans as a PD model with α­syn pathology, which was the other aim of this investigation.
When treating C. elegans exposed to α­syn with hops, hops reversed or subdued any 
behavioural changes possibly caused by α­syn.  In the case of DDP1, the worms treated with hops
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were twice the size of untreated DDP1 and the movement speeds about twice as fast.  This study 
recommends secondary recordings to monitor development, which may reveal the cause of any 
changes in body size, be it increased development rate or final growth size.  No changes were 
observed in the hops treated N2 fed with E­syn suggesting that E­syn may not have an impact on C. 
elegans via α­syn toxicity.  Finally, hops reversed the increased speeds in N2 exposed to aggregated 
α­syn, signifying a possible reaction between α­syn and hops. The final aim of this study was to 
explore the effects of hops in an in vitro and in vivo model, both of which revealed a possible 
relationship between α­syn and hops, however, confocal study of the treated worms is 
recommended to supplement these findings.
In the screening process, multi­validation is required to provide evidence of treatment 
effects on a disease target.  This study showed that the use of ThT assays and C. elegans behavioural 
assays are useful in detecting potential PD treatments.  By adding a few additional steps such as 
multiple recordings over time and using electron microscopy/immunostaining, any changes detected 
in the assays may be used as evidence for larger animal studies or clinical trials.
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9 Appendix
9.1 Full gel image with lane descriptions
Figure 9.1 The gels (BioRad Mini­PROTEAN TGX Stain­Free Gels #456­8123) above were run at 200 V for 30 min, stained 
using Bio­Rad Silver Stain Plus #161­0449 and were imaged using Bio­Rad ChemiDoc MP System with Image Lab. Samples 
were taken after a microplate run, prepared using 4X sample buffer to sample and were diluted using running buffer (See 
Methods for buffer contents/concentrations). All samples contain 1 mg/mL a­syn dissolved in ThT buffer with a glass bead.
1) a­syn and buffer only,
2) 2.5% cold hops with a­syn
3) 5% cold hops with a­syn
4) 10% cold hops with a­syn
5) 20% cold hops with a­syn
6) 10% cold hops without a­syn
7) 2.5% CO2 hops with a­syn
8) 5% CO2 hops with a­syn
9) 10% CO2 hops with a­syn
10) Bio­Rad Precision Plus Protein Unstained Standards #161­0363
11) 10% cold filtered hops without a­syn
12) 2.5% cold filtered hops with a­syn
13) 5% cold filtered hops with a­syn
14) 10% cold filtered hops with a­syn
15) 20% cold filtered hops with a­syn
16) 2.5% hot hops with a­syn
17) 5% hot hops with a­syn
18) 10% hot hops with a­syn
19) a­syn and buffer only
20) Bio­Rad Precision Plus Protein Unstained Standards #161­0363.
